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Chapter 1:  Abstract 
 
 
Background: Lower respiratory tract infections 
(LRTI) are a leading cause of morbidity and 
mortality in young children. A number of new 
viruses associated with LRTI in young children 
have recently been discovered. These include 
Human Bocavirus (HBoV), Human 
Polyomavirus strains WU (WUPyV) and KI 
(KIPyV) and Human Coronavirus strains NL63 
(HCoV-NL63) and HKU-1 (HCoV-HKU-1). There 
is, however, limited data on the epidemiology 
of these newly discovered respiratory viruses 
in industrializing country settings, including 
South Africa. 
Objective: To determine the clinical 
epidemiology of HBoV, HCoV-NL63, HCoV-
HKU1, HCoV-OC43, HCoV strain 229E (HCoV-
229E), WUPyV, KIPyV and human rhinovirus 
(HRV) in young children.  
Methods: Nasopharyngeal aspirates where 
taken from children who were hospitalized at 
Chris Hani Baragwanath Hospital between 
February 2000 and January 2002 with severe 
LRTI. These children had been enrolled in a 
double-blind, randomized, placebo-controlled 
trial of a 9-valent pneumococcal conjugate 
vaccine (PCV). Nucleic acid extraction was 
undertaken from archived nasopharyngeal 
aspirate samples and the respiratory viruses 
identified using real time duplex PCR. The 
study was limited to examining samples from 
HIV uninfected children with LRTI who were 
less than 24 months of age. 
Results: Overall, samples were available for 
895 of 1565 nasopharyngeal aspirates, from 
children hospitalized with LRTI, collected from 
February 2000 to January 2002. A comparison 
between those LRTI episodes for which 
samples were unavailable compared to those 
for which samples were available indicated 
that children in whom samples were 
unavailable were younger than children with 
available samples (9.9±6.4 vs. 11.8±6.5 
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months; p<0.0001). In addition there was a 
higher frequency of wheezing episodes in 
children for whom samples were unavailable 
(60.4 vs. 54.6%; p=0.022).  
The overall prevalence of the viruses in 
children with any LRTI were 33.2% for HRV, 
21.2% for HBoV, 16.1% for WUPyV, 10.1% for 
HCoV-OC43, 7.0% for KIPyV, 3.2% for HCoV-
NL63, 2.6% for HCoV-HKU-1, and 0.6% for 
HCoV-229E. There was a higher probability of 
detecting a selected virus in LRTI episodes 
among PCV-compared to placebo-recipients 
for HBoV (24.2% vs. 18.2%, respectively; 
p=0.028) and HRV (36.7% vs. 29.5%, 
respectively; p=0.023). Conversely, viruses 
identified more frequently in LRTI episodes 
among children who received placebo 
compared to PCV-recipients included WUPyV 
(20.2% vs. 12.1%, respectively; p=0.001), 
KIPyV (10% vs. 4.2%, respectively; p=0.001), 
HCoV-OC43 (14.1% vs. 6.2%, respectively; 
p≤0.0001) and HCoV-HKU1 (4.5% vs. 0.1%, 
respectively; p≤0.0001). 
Overall, the prevalence of the studied-viruses 
in the subgroup of children categorized as 
having bronchiolitis was 33.8% for HRV, 33.4% 
for WUPyV, 22.3% for HBoV, 11.1% for HCoV-
OC43, 5.3% for KIPyV, 2.3% for HCoV-NL63, 
1.9% for HCoV-HKU1 and 0.4% for HCoV-229E. 
Viruses more commonly identified in placebo- 
compared to PCV-recipients among children 
hospitalized with bronchiolitis included 
WUPyV (20.0% vs. 12.3%, respectively; 
p=0.029), HCoV-OC43 (15.9% vs. 7.2%, 
respectively; p=0.004) and HCoV-HKU1 (3.6% 
vs. 0.5%, respectively; p=0.015).  
The prevalence of the newly studied viruses in 
the subgroup of children categorized as having 
clinical pneumonia was 30.8% for HRV, 20.3% 
for HBoV, 16.4% for WUPyV, 9.1% for HCoV-
OC43, 8.6% for KIPyV, 4.1% for HCoV-NL63, 
3.2% for HCoV-HKU1 and 0.6% for HCoV-229E. 
Viruses identified more frequently among 
placebo- compared to PCV-recipients, in those 
with clinical pneumonia, included WUPyV 
(20.4% vs. 11.9%, respectively; p=0.013), 
KIPyV (12.7% vs. 4.1%, respectively; p=0.001), 
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HCoV-HKU1 (5.3% vs. 0.9%, respectively; 
p=0.008). Conversely, HCoV-OC43 was 
identified more frequently in children with 
clinical pneumonia among PCV- (5.0%) 
compared to placebo-recipients (2.7%, 
p=0.004).  
There were seasonal peaks, during autumn-
winter months (April to June), in the detection 
of HRV, WUPyV, HCoV-OC43, HCov-NL63 and 
HCoV-HKU1, whereas KIPyV, HBoV and HCoV-
229E were identified perennially. 
Conclusion: Prevalence of respiratory viruses 
is high in industrializing countries and the 
presence of these viruses is frequently 
associated with co-infections of more than 
one etiological agent. In industrializing 
countries such as in South Africa, the recently 
identified respiratory viruses play a role in 
development of pneumonia. 
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Chapter 2: Background 
 
 
Acute respiratory infections (ARI) are the main cause of childhood hospitalization and death 
worldwide, particularly in industrializing countries. In 2000 global estimates of child death showed 
that 1.9 million children died from ARI and 70% of those occurred in industrializing countries 
(Williams et al 2002). In 2008 an estimated 5.97 million children less than 5 years of age died due to 
infectious diseases, including 1.57 million (15% of all under-5 years childhood deaths) because of 
pneumonia in Africa, Eastern Mediterranean, Southeast Asia, and the Western Pacific. Whereas in 
industrialized countries including Europe and America, 10% of childhood deaths were due to 
pneumonia (Black et al 2010). The study by Black et al. also showed that one third of neonatal deaths 
were due to various infectious causes, including pneumonia which accounted for 4% of deaths in 
neonates (Black et al 2010). A systematic review on the burden of pneumonia indicated that the 
incidence of pneumonia in low-income countries was 0.28 episodes/child-year in children less than 5 
years of age (Rudan et al 2004). This incidence results in 150.7 million new cases of clinical 
pneumonia, with 11-20 million (7-13%) severe cases requiring hospitalization. However, in developed 
countries the incidence of community acquired pneumonia was 0.026 episodes/child-year, resulting 
in 2 million new cases in children less than 5 years of age (Rudan et al 2004).  
 
Major presentations of lower respiratory tract infections (LRTI) that account for the global burden of 
disease among young children are bronchiolitis and pneumonia, as defined by the Child Health 
Epidemiology Reference Group under World Health Organization (Rudan et al 2004). The high 
mortality due to LRTI in industrializing countries is also associated with a high incidence of 
pneumonia in these countries (Jokinen et al 1993; Weigl et al 2003). The heightened susceptibility to 
pneumonia in children from developing countries may include increased exposure to risk factors such 
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as indoor pollution, overcrowding, malnutrition, low coverage with measles vaccine and other 
vaccines targeting respiratory pathogens, low birth weight and non-exclusive breastfeeding (Bruce et 
al 2007; Mulholland et al 2008; Rudan et al 2008).  
 
Advances in medical science have led to the development of vaccines that target known bacterial 
pathogens including Streptococcus pneumoniae and Haemophilus influenzae type b (Hib). Vaccines 
such as the 9-valent pneumococcal conjugate vaccine (PCV) have been shown to reduce the 
incidence of radiologically confirmed pneumonia in HIV-uninfected children under 5 years by 85%, 
and by 65% in HIV-infected children in South Africa (Klugman et al 2003). Pneumococcal conjugate 
vaccines were developed following the successful use of Hib conjugate vaccine in children. PCV-7 
(Prevenar) was developed from the seven serotypes that caused the most invasive pneumococcal 
disease in children in the United Stated and it consists of seven pneumococcal polysaccharides 
conjugated to an immunogenic carrier protein (Zangwill et al 1996). It has been shown that PCV-7 
reduces overall invasive pneumococcal disease by 89.1% (Black S. 2000), with an overall reduction of 
20.5% in chest radiograph infiltrates and a 4.3% overall reduction in clinically diagnosed pneumonia 
(Black et al 2002). In addition a 9-valent pneumococcal conjugate vaccine (PCV-9) was used in Phase 
III clinical trials in South Africa and Gambia. The PCV-9 includes two extra serotypes in addition to the 
7 serotypes from Prevenar vaccine thus resulting in the 9-valent PCV. Using different definition of 
pneumonia PCV has been shown to reduce pneumonia by 58.1% (Madhi et al 2005) and 76.5% (Cutts 
et al 2005). Hence, these studies have shown that PCV is effective at preventing radiologically 
confirmed pneumonia (Klugman et al 2003; Madhi et al 2005).  
 
PCV has also been shown to reduce superimposed pneumococcal infections in children who had 
been infected with respiratory viruses (Madhi et al 2004). In South Africa the PCV vaccine trial 
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showed that children with respiratory virus were 31% less likely to be hospitalized for pneumonia. 
Specifically, PCV reduced pneumonia associated with influenza A/B by 45%, parainfluenza viruses 
(types 1-3) by 44% and respiratory syncytial virus by 22% (Madhi et al 2004). This study indicated that 
there was no association of all cause and virus specific bronchiolitis between placebo and PCV-
vaccinated children. Hence, data from Madhi et al., implies that pneumonia associated with viruses is 
a result of bacterial co-infections (Madhi et al 2004). In agreement other studies have shown that 
hospitalized children with pneumococcal pneumonia may also have viral respiratory infections 
(Madhi et al 2004; Peltola et al 2004). 
 
Respiratory infections are classified by their symptoms and anatomical site of presentation: upper 
respiratory tract infections and lower respiratory tract infections. Upper respiratory tract infections 
(URTI) are infections that occur in sinus, pharynges, epiglottis and laryngotrachie. These infections 
are self limiting and transitory. They are caused by various organisms including viruses. The viruses 
infect the upper respiratory tract by invading the mucosa epithelial cells causing destruction, 
sloughing and loss of cilliary activity. Hence this leads to the obstruction of the paranasal sinuses 
resulting in sinusitis. Large amounts of proteins and immunoglobulins are excreted as a result of 
cytokines response. The destruction of the epithelial lining due to virus invasion also contributes to 
the development of otitis media, as the destruction increases the chance of normal bacterial flora of 
the mucosa to multiply and invade the epithelial lining. Symptoms associated with URTI include 
sneezing, sore throat, nasal discharge, cough, headache and myalgia. The symptoms occur after 
incubation period of 48-72 hours and vary with age and type of virus; complications are rare in URTI 
(Baron S 1996).  
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The lower respiratory tract infections (LRTI) include bronchitis, bronchiolitis and pneumonia. 
Bronchitis and bronchiolitis are due to the inflammation of the mucosa in the bronchial tree, the 
mucosa becomes hyperemic and edematous and copious bronchial secretions are produced. This 
leads to the loss of mucociliary function and destruction of respiratory epithelium. Eventually the 
bronchial walls thicken and the bronchial lumen is narrowed due to excretion of necrotic material, 
resulting in the obstruction of airways. The narrowing of the bronchial lumen is common in children. 
The symptoms of bronchitis and bronchiolitis include: cough, coryza, fever, increased respiratory 
rate, grunting, wheezing and retraction of chest walls. Pneumonia is the inflammation of the lung 
parynchema and can be grouped into lobar pneumonia (alveolar processes of the entire lobe) and 
bronchopneumonia (alveolar processes of parts of the lobe). Aerosols of the pathogen causing 
pneumonia are inhaled into the lower respiratory tract where they infect and multiply in the alveoli, 
and cause various symptoms including: fever, chest pain, cough, shortness of breath and production 
of sputum. Other symptoms depend on the type of infectious organism and age of patient; these 
include confusion, headache, abdominal pain, nausea, vomiting and diarrhoea. 
 
The common symptoms occurring in both upper and lower respiratory tract infection can be 
described as common cold like symptoms and studies have shown that the only difference between 
the viral infections causing common cold like symptoms and pneumonia, is the duration of the 
incubation period (Tyrrell DAJ 1959; Tyrrell DAJ 1993). 
 
Pneumonia may be caused by a diversity of pathogens, including viruses, bacteria and fungi. Initial 
studies identified Streptococcus pneumoniae and Haemophilus influenzae as the main bacterial 
causes of pneumonia (Del Beccaro et al 1992). Other bacteria causing pneumonia include 
Staphylococcus aureus, non-typhoid Salmonella species and less frequent other gram negative 
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pathogens such as Klebsiella pneumoniae and Eschericia coli  (Bartlett JG 2008). S. pneumoniae is the 
most common bacterium identified in most age groups of children with pneumonia in the absence 
PCV vaccination (Mulholland et al 1999; Klugman et al 2003). Recent studies have, however, 
indicated that a significant proportion of pneumococcal pneumonia may be associated with 
concurrent respiratory viral infections (Henrickson 1998; Madhi et al 2004; Arnold et al 2006; Fry et 
al 2007). The focus of this project was to characterize the clinical epidemiology of recently discovered 
respiratory viruses in South African children hospitalized for LRTI, for which there is limited 
information from South Africa (Smuts and Hardie 2006; Smuts et al 2008; Venter et al 2009). 
Studies have shown that the prevalence of respiratory viruses in children with pneumonia decreases 
with age, with highest prevalence in infants (Henrickson KJ. Viral pneumonia. In: Wald E 1998). 
Respiratory viruses have been identified in 50% to 90% of young children hospitalized with LRTI 
including bronchiolitis and pneumonia (Henrickson KJ. Viral pneumonia. In: Wald E 1998; Arnold et al 
2006; Fry et al 2007). Respiratory viruses including respiratory syncytial virus (RSV), parainfluenza 
viruses (PIV) 1 and 3, adenoviruses (AdV), influenza A, rhinovirus (RV), and human metapneumovirus 
(HMPV), have been collectively identified in up to 90% of pneumonia cases occurring in the first year 
of life, whereas this declines to 50% in school-aged children and 12% in adults (Murphy et al 1981; 
Denny et al 1986; Cilla et al 2008; Smuts et al 2008).  
 
Traditionally, isolation and identification of viral relied mainly on cell culture or antigen detection by 
immunofluorescence assays. Cell culture was considered the gold standards for the identification of 
respiratory viruses because of its specificity. However it has technical limitations related to timeliness 
of sample preparation, sample transportation and cell culture conditions including cell-lines used in 
culture. Additionally, not all respiratory viruses such as RV are easily cultured due to large number of 
serotypes (Johnston et al 1995). Hence, further molecular and immunological tests were explored to 
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determine the role of viruses in pneumonia cases. Immunological assays such as direct and indirect 
immunofluorescence have been developed to detect viral antigens. Although immunofluorescence 
assays are as specific as cell culture, they have limitations, including the variability of sensitivity in 
identifying different viruses which range between 48 to 100% (Wong et al 1982) 
 
The discovery of new respiratory viruses has gained momentum following advances in molecular 
detection of potential pathogens compared to the past reliance on culture and antigen detection of 
respiratory viruses. Polymerase chain reaction (PCR) has improved the sensitivity and specificity of 
detection of viral respiratory pathogen from different sample types (Heikkinen et al 2002; Lambert et 
al 2008). Real time PCR is rapid, more sensitive and specific in detecting respiratory viruses than 
antigen detections and cell culture (Jennings et al 2004). Real time PCR results from patients in a 
clinical setting indicates a true reflection of the occurrence of a respiratory infection (Jartti  and 
Korppi 2011). Another advantage with real time PCR techniques includes the ability to detect 
multiple viruses simultaneously also including viruses that have multiple serotypes such as RV. 
Commercial kits are available for multiplex PCR assays for most previously known respiratory viruses. 
More recently a number of new respiratory viruses have been identified, and they have been variably 
associated with pneumonia in industrialized country settings. The newly discovered respiratory 
viruses studied in this project are: human coronavirus NL63 (HCoV-NL63) discovered in 2004 (van der 
Hoek et al 2004)), human coronavirus HKU-1 (HCoV-HKU1) discovered in 2005 (Woo et al 2005; 
Sloots et al 2006), human bocavirus (HBoV) discovered in 2005 (Allander et al 2005), human 
polyomavirus WU (WUPyV) and KI (KIPyV) discovered in 2007 (Allander et al. 2007; Gaynor et al 
2007). We also included in this study the human coronavirus-229E (HCoV-229E), human coronavirus-
OC43 (HCoV-OC43) and human rhinovirus (HRV) for which there is also only limited information from 
developing countries. 
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2.1  Human Bocavirus 
 
2.1.1  Molecular background 
Human bocavirus (HBoV) belongs to the Parvoviridae family, subfamily Parvovirinae and 
genus Bocavirus. The family of Parvoviridae consists of the subfamilies densovirinae and 
parvovirinae. The Parvovirinae subfamily consists of 5 genera including the genus Bocavirus 
(Allander et al 2005). The genus Bocavirus consists of bovine parvovirus (BPV), canine minute 
virus (MVC) and human bocavirus. Bocavirus is the second virus from parvoviridae family that 
is known to cause disease in humans, after the parvovirus B19 which causes erythema 
infectiosum in childhood. The name evolved from two members of Bocavirus genus, the 
bovine (“bo”) and canine (“ca”) parvoviruses. Bocaviruses’ DNA is distinct from the non-
human viruses but shares homology with the bovine virus and canine virus. The genomic 
organization of bocavirus consists of two major open reading frames (ORF), encoding the 
viral capsid proteins (VP1/VP2) and non-structural genes (NS1 and NP1). Another additional 
ORF is located in the middle of HBoV genome encoding a nonstructural protein (NP-1) that 
was found to have 47% amino acid similarity to that of MVC and BPV (Allander et al 2005). 
Bocavirus surface proteins and non-structural genes are highly conserved (Lau et al 2007). 
Thus molecular epidemiology of bocavirus reveals very little changes within the virus 
genome. A study in California has shown that there is little variation in the NP1 and NS1 
genes of bocavirus over a period of 21 months (Arnold et al 2006). The two genotypes 
identified in the later study and were identical to genotype ST1 and genotype ST2 previously 
described (Allander et al 2005; Kesebir et al 2006). In South Africa, phylogenetic analysis of 
the viral capsid gene revealed that the strains from South Africa (Smuts and Hardie 2006) 
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align closely with genotype ST2 previously described (Allander et al 2005). Hence this 
illustrates that bocaviruses circulating around the world are similar. A single lineage of HBoV 
has been shown to be responsible for both respiratory tract and enteric infections in humans 
(Lau et al 2006; Lau et al 2007).  
 
2.1.2  Clinical Significance 
A summary of selected studies undertaken in children on HBoV is described in Table 2.1. 
HBoV has been isolated from pooled nasopharyngeal aspirate specimens from children with 
pneumonia, bronchiolitis and asthma (Allander et al 2005; Kesebir et al 2006; Fry et al 2007). 
Studies have reported prevalence of HBoV to be 1 to 8% in children less than 5 years with 
pneumonia (Allander et al 2005; Smuts H and Hardie D 2006; Fry et al 2007) and as high as 
19% in children with acute wheezing (Allander et al 2007). Clinical symptoms associated with 
bocavirus include hypoxia, fever, acute wheezing and abnormal findings on chest radiographs 
(Kesebir et al 2006). Most studies indicate that HBoV as an autumn/winter seasonality 
(Allander et al 2005; Smuts H and Hardie D 2006). HBoV has been identified globally in 
children with LRTI, including in a previous study from South Africa, Table 2.1 (Allander et al 
2005; Lu et al 2006; Smuts H and Hardie D 2006; Lau et al 2007). Co-infections of HBoV with 
other respiratory viruses are common (37% - 83%) in many studies (Allander et al 2005; 
Kesebir et al 2006; Smuts H and Hardie D 2006; Fry et al 2007). High viral loads of HBoV are 
associated with pneumonia and acute wheezing in children (Allander et al 2007; Fry et al 
2007). An another study it was recommended that HBoV has a similar epidemiological profile 
as RSV in children (Manning et al 2006).  
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The role of HBoV as a potential pathogen causing pneumonia is, however, controversial. 
Kesebir et al., reported the presence of HBoV in 5% of specimens that tested negative for 
common respiratory viruses and in 0% of specimens from asymptomatic participants (Kesebir 
et al 2006). In contrast, HBoV was identified in 3.9% of children with LRTI and 1% of 
asymptomatic children in Thailand (Fry et al 2007). A study in Netherlands also identified 
HBoV in 5.1% of children with LRTI and 4.8% in children less than 5 years of age without LRTI 
(van de Pol et al 2009). In addition, HBoV has been identified in stool specimens in children 
with diarrhoea (Arnold et al 2006; Lau et al 2007). There have only been limited studies in 
industrializing countries which have examined the prevalence of HBoV in either 
asymptomatic or symptomatic individuals. In South Africa, HBoV was identified in 11% (38 
out of 341) of children less than 2 years old diagnosed with pneumonia (Smuts H and Hardie 
D 2006). 
   
Zelda Radebe  Page 24 
 
Table 2.1:  Summary of clinical studies on Human Bocavirus 
Reference Study 
site 
Study 
Year 
n Illness 
description 
HBoV 
Prevalence 
Age in 
years 
Co-infections 
(Allander 
et al 
2005) 
Sweden 05 540 Asthma, 
wheezing & 
bronchiolitis 
3.1%  266 
paediatrics 
& 112 
adults 
Out of 14: 2 HBoV 
& RSV and 1 HBoV 
& Adenovirus 
(Kesebir 
et al 
2006) 
USA 04 425 LRTI 5.2% <2 Not given  
(Fry et al 
2007) 
 
Thailand 
 
07 1680 Pneumonia 4.9% 0-65 Out of 22 
positives: 1 HCoV-
NL63 in control 
patient, 4 Infl A, 3 
HRV, 2 
Adenovirus, 1 
HPIV, 1 HPIV 3/Infl 
B, 1 HPIV 
3/Adenovirus, 1 
HMPV/HRV/HCoV-
NL63  
(Smuts 
and 
Hardie 
2006) 
South 
Africa 
06 35 LRTI 
including 
pneumonia 
11% 2-12 Co-infections with 
RSV 35%, HRV 
10%, Flue 13%, 
HCoV 8% & 
AdV3%. 
(Manning 
et al 
2006) 
United 
Kingdom 
05-06 924 URTI 8.2% <5 7 AdV & 6 RSV, 
AdV & 1 HPIV 1-3, 
4 Influ B & Influ A 
1.  2 RSV-
Adenovirus 
(Lau et al 
2007) 
China 
 
04-05 400 Hospitalized 
patient  
6.5% 
 
<5  14/93 HBoV-HRV 
and 2/93 HBoV-
HMPV 
LRTI: lower respiratory tract infection 
URTI: upper respiratory tract infection 
n study population size 
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2.2  Human Polyomaviruses: WUPyV and KIPyV 
 
 
2.2.1 Background 
Human polyomavirus belong to family Polyomaviridae; are small non-enveloped double-
stranded DNA viruses that infect a variety of avian, rodent and primate species. In 
immunocompromised patients, viruses from the family Polyomarividae induce disease and 
can be oncogenic (Gardner et al 1971; Padgett et al 1971; Allander et al 2007; Gaynor et al 
2007; Feng et al 2008). There are five polyomaviruses that are known to date and these are: 
BKV (Gardner et al 1971), JCV (Padgett et al 1971), KIPyV (Allander et al. 2007), WUPyV 
(Gaynor et al 2007) and MCV(Feng et al 2008). BKV causes nephropathy and is associated 
with renal and urinary tract disorders such as tubular nephritis that can lead to hemorrhagic 
cystitis. JCV causes primary multifocal leukoencephalopathy (Arthur et al 1986). Molecular 
genetics of the WUPyV and KIPyV indicate that the two viruses are similar. Both viruses 
define a novel branch within the Polyomaviridae family, and the WUPyV/KIPyV branch is 
closely related to primate polyomaviruses (Gaynor et al 2007). 
 
2.2.2 Clinical significance 
The WUPyV and KIPyV are the only polyomaviruses from the Polyomaviridae family that have 
been isolated from nasopharyngeal aspirates of children with LRTI. A sero-prevalence study 
indicated seroprevalence in children under 5 years of age of 54% for WUPyV and 56% for 
KIPyV, similar results were obtained in adults older than 21 years for KIPyV (55%) for and 
WUPyV (69%) (Kean et al 2009). This study indicated that infection with these viruses occur 
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early in childhood. Another study identified WUPyV in 2.07% and KIPyV in 1.07% of patients 
under 15 years of age with upper or lower respiratory infections and >45 years with upper 
respiratory infections (Abedi Kiasari et al 2008). It has been suggested that polyomaviruses 
may establish persistent infections in the respiratory tract and become reactivated during 
respiratory disease of any cause (Abedi Kiasari et al 2008). 
 
A few selected recent published studies on polyomavirus, summarized in Table 2.2, indicate 
that the prevalence of KIPyV ranges from 1.5% to 2.5% in children less than 5 years of age 
with LRTI (Bialasiewicz et al 2007; Norja et al 2007) and the prevalence of WUPyV ranged 
from 0.4% to 7% (Han et al 2007; Lin et al 2008). The identification of KIPyV and WUPyV and 
its association in the pathogenesis of LRTI in children is also controversial because of a similar 
prevalence found in ill and asymptomatic children. KIPyV and WUPyV were identified in 0% 
and 2.6%, respectively, in children with LRTI; and 4.8% and 2.4% respectively in 
asymptomatic children (van de Pol et al 2009). Another study identified WUPyV in 4.2% of 
asymptomatic children compared to 7% in children with LRTI (Han et al 2007). A comparison 
of asymptomatic and symptomatic patient was performed in another study, and it was found 
that the frequency of KIPyV/WUPyV in children without LRTI was higher (11%) compared to 
in children with LRTI (7%), although asymptomatic children were older and 
immunosuppressed compared to the LRTI cases (Norja et al 2007). 
 
Polyomaviridae is known to induce disease in immunocompromised individuals. A cross-
sectional study conducted in 300 South African children with LRTI identified WUPyV in 7% 
and KIPyV in 1% in children less than 2 years old, among whom the prevalence of HIV was 
57% and 33% in WUPyV and KIPyV cases, respectively (Venter et al 2009). The study also 
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identified 5 strains of WUPyV that were unique to South Africa, which clustered with 4 
genotypes of existing strains. Most of the WUPyV strains from the study clustered into 
genotype 1. The KIPyV strains from South Africa were identical to that in Sweden and 
Australia (Venter et al 2009). 
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Table 2.2    Summary of clinical studies on Human Polyomaviruses 
 
RTI: respiratory tract infection 
ARTI:  acute respiratory tract infection 
LRTI : lower respiratory tract infection 
a Co-infections were determined in 15/21 (71%) and 2/3 of WUV- and KIV-positive specimens, 
respectively 
b HMPV and HBoV were co-infection with WUPyV, HPIV and RSV-B were co-infection with KIPyV 
Reference Study site Study 
Year 
n Illness 
descriptio
n 
Prevalence of 
Polyomaviruses 
Age in 
years 
Co-
infections 
(Allander 
et al 2007) 
Sweden 04-05 1300 RTI 0.5% 0-90 3 RSV, 1 
HMPV, 1 
Influ A 
(Gaynor et 
al 2007) 
Australia 
and USA 
03 
Austr
alia, 
03-06 
(USA) 
245 
(Aus
trali
a)  
410 
USA 
ARTI 3.6% (Australia) 
1.2% (USA) 
4-53 
(Austra
lia) 
4-51 
(USA) 
HBoV and 
HRV 
(Bialasiew
icz et al 
2007) 
Australia 02-03 951 RTI 2.5% KI 0-95 4 RSV, 1 
Influ A, 1 
HMPV 
(Norja et 
al 2007) 
United 
Kingdom 
07 893 Symptom
atic & 
asympto
matic 
group 
1.11 WUPyV/ 
1.56 % KIPyV 
< 5 120 RSV, 
4 Influ A, 
46 Influ B, 
35 HPIV, 
80 AdV 
(Venter et 
al 2009) 
South 
Africa 
06-07 300 LRTI WUPyV 7%  & 
KIPyV 1% 
0-72 a6 HRV, 3 
HBoV, 2 
RSV, 
3HBoV-
AdV, 2 PIV 
1-3, 2 
Influ A 
(Lin et al 
2008) 
China 05-06 278 Acute 
LRTIs 
0.4% WUPyV & 
0% KIPyV 
< 5 Not given 
(Abedi 
Kiasari et 
al 2008) 
United 
Kingdom, 
06-07 371 RTI KIPyV 2.7% & 
WUPyV 1.08% 
0-79 b4 HMPV, 
1 HBoV, 1 
PIV1, 1 
RSV-B 
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2.3  Human Coronaviruses: HCoV-NL63, HCoV-OC43, HCoV-229E and HCoV-        
HKU1
 
 
2.3.1  Background 
Human Coronaviruses are spherical enveloped viruses. Their envelope consists of studded 
glycoproteins that enclose a matrix which contains a single stranded positive sense RNA 
associated with nucleoproteins. The glycoproteins have antigenic epitopes that are 
recognized by the host immune system and account for the diversification of Coronaviruses. 
The human Coronaviruses belong to the family of Coronaviridae as a result of the 
glycoprotein appearance on the electron microscope (Baron S 1996). The genomic structure 
of Coronaviruses comprises regions  1a and 1b (encodes non-structural proteins), S (encodes 
Spike protein), ORF3, E (encodes envelope protein), M (encodes membrane proteins) and N 
(encodes nucleocapsid protein) genes (van der Hoek et al 2004). Human coronaviruses can 
be divided in three distinct groups: Group I coronaviruses are HCoV-229E and HCoV-NL63, 
group II coronaviruses are HCoV-OC43 and HCoV-HKU-1, group III consist of severe acute 
respiratory syndrome (SARS) virus, which represents an early split from group II (Pyrc et al 
2007). In group I all genes for HCoV-NL63 share sequence similarity with HCoV-229E with the 
exception of the M gene (van der Hoek et al 2004).The GC content of Coronaviruses genome 
range from 32% (group II) to 34% (group I) (van der Hoek et al 2004; Woo et al 2005). 
 
SARS was the first of the Coronaviruses to have crossed the species barrier from infected 
civet cats to humans, and to cause a severe lung disease (Li  et al 2005). In 2003, SARS caused 
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800 deaths and 8000 illnesses and has been shown to be absent from human populations 
(van der Hoek et al 2007). Coronaviruses HCoV-OC43 and HCoV-229E have been previously 
associated with mild URTI. The later viruses have been circulating in human populations for 
several years, these viruses are easily cultured and have been shown to cause disease in 
humans (Tyrell DAJ and Bynoe ML 1965), hence following Koch’s postulate stating that: a 
microorganism must be present in organisms suffering from disease, the microorganism 
must be isolated from a diseased organism and grown in pure culture, the microorganism 
should cause disease when introduced into a healthy organism, and lastly the microorganism 
must be re-isolated from the inoculate of diseased host and shown to be identical to the 
original causative agent. HCoV-NL63 was initially isolated from a 7 month old girl with coryza, 
conjunctivitis, fever and bronchiolitis (van der Hoek et al 2004) and HCoV-HKU1 was 
discovered in respiratory secretions from a 71 year old man with chronic respiratory tract 
disease, hospitalized with fever, cough and infiltrate chest radiograph (Woo et al 2005). 
HCoV-NL63 has been shown to grow in monkey kidney culture (van der Hoek et al 2004). 
HCoV-HKU1 does not fulfil Koch’s postulate due to the unavailability of cell culture methods 
to grow the viruses and there is no animal model available. Hence it is important to establish 
significant association between the virus and the disease using a control group. Most of the 
studies of the later viruses do not have a control group involved in the investigation; hence 
only indicate the occurrence of the virus in ill patients. 
 
The human coronaviruses have a worldwide distribution. These respiratory viruses generally 
cause mild symptoms, but have a potential to cause severe disease in young children, the 
elderly and immunocompromised individuals (van Elden et al 2004). Coronaviruses cause 
infection by invading the respiratory epithelial cells which cause cilia damage. This triggers an 
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inflammatory response, resulting in nasal secretion, inflammation and swelling. Common 
symptoms of coronavirus infection are common cold symptoms including sneezing and 
obstruction of the airways. Immunity against coronavirus infection does not persist; 
individuals infected with coronaviruses can be infected again with the virus later in the 
season (Baron S 1996). Coronaviruses infections occur primarily in the autumn and winter 
seasons.  
 
2.3.2  Clinical Significance 
Infections with Coronaviruses have been documented in various studies from both children 
and adults, including symptomatic and nonsymptomatic individuals. Prevalence of HCoV-
229E, HCoV-NL63 and HCoV-OC43 was 0%, 5% and 5% respectively in children less than 2 
years of age with LRTI and 0%, 1.4% and 2.8%, respectively in children with URTI (Talbot et al 
2009). The latter study suggested that HCoV-OC43 and HCoV-NL63 may be associated with 
LRTI in children. In support of the association another similar study indicated that the later 
viruses occur in high frequencies in children with LRTIs and URTIs and that these viruses are 
prone to cause severe illness in children (van Elden et al 2004). HCoV-NL63 was frequently 
associated with croup together with influenza virus or PIV-1, in children less than 5 years of 
age with acute respiratory disease (Choi et al 2006). In another study the prevalence of 
HCoV-NL63 in children under 16 years of age with acute respiratory disease was 1.7%, in 
which 31% of the cases presented with croup and 21.4% had bronchiolitis (Han et al 2007). 
The prevalence of HCoV-HKU1 was 19.2% in patients with acute respiratory disease (Gerna et 
al 2007). Although a high prevalence of HCoV-HKU1 was reported some studies have 
indicated lower detection rates of HCoV-HKU1 (Woo et al 2005). However it is suggested that 
prolonged study periods for investigation of respiratory tract infection should be 
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implemented in order to estimate prevalence of respiratory infection (Lau et al 2007). HCoV-
NL63 and HCoV-HKU infections have been shown to occur in 18% and 30% respectively of 
febrile seizure cases in children with acute respiratory infection (Chiu et al 2005; Lau et al 
2006; van der Hoek et al 2006). HCoV-NL63 has been implicated in kawasaki disease, but no 
confirmatory study can link the virus to the disease (van der Hoek et al 2006). In group I 
infections HCoV-229E antibodies have been shown to occur in lower levels as compared to 
the HCoV-NL63, whereas in group II infections HCoV-OC43 induces high levels of antibodies 
compared to HCoV-HKU1 (Lau et al 2006). 
 
There are few data for HCoV-NL63 and -HKU1 from South Africa. A study by describing the 
prevalence of HCoV-NL63 found 2.4% HCoV-NL63 positive children with acute wheezing 
(Smuts et al 2008). The study also indicates co-circulation of two genotypes HCoV-NL63 A 
and B lineage; similar findings were observed in Hong Kong (Woo et al 2005).  
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Table 2.3:  Clinical studies on Human Coronaviruses  
 
RTI:  respiratory tract infection 
ALRTI: acute lower respiratory tract infection 
LRTI:  lower respiratory tract infection 
URTI:  upper respiratory tract infection 
(Gerna et al 2007) identified HCoV co-infections was identified in 29% of children in first year of life 
and co-infections were associated with severe respiratory syndromes. 
(Han et al 2007) showed that HCoV-NL63 positive patients were diagnosed as croup in 9 (64.2%), 
bronchiolitis in 3 (21.4%), bronchial asthma exacerbation in 1, and pneumonia in 1. Only single 
infections were observed from the study 
# Co-infections were investigated for HBoV with other viruses 
Referen
ce 
Study site Study 
Year 
n Illness 
description  
Prevalence of 
Coronaviruses 
Age 
in 
years 
Co-
infections 
(van der 
Hoek et 
al 2004) 
Netherlands 03 614 URTIs or 
LRTIs  
1.14% HCoV-
NL63 
<1 1 RSV and 
1 
Pneumocy
stis carinii 
(van 
Elden et 
al 2004) 
Netherlands 03 545 RTI 11% of  Not  
given 
Not given 
(Choi et 
al 2006) 
Korea 00-05 515 ARTI 1.6% HCoV-
NL63  
≤5 #Not given 
for 
Human 
coronavir
uses  
(Han et 
al 2007) 
United 
Kingdom 
04-06 827 ARTI  1.7% HCoV-
NL63 
<5 Not given 
(Gerna 
et al 
2007) 
Italy 03-05 823 RTI 50.9% HCoV-
OC43, 26.4% 
HCoV- 229E,  
17% HCoV-
NL63, 5.7% 
nontypeable 
1-21 Not given 
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2.4  Human Rhinovirus 
 
 
2.4.1  Molecular background 
Human rhinovirus (HRV) is a small non-enveloped single stranded positive sense RNA virus 
belonging to the Picornaviridae family and Enterovirus genus. previously There were 100 
immunologically distinct serotypes of rhinoviruses of which 74 belong to HRV-A species, 25 
to HRV-B species and a single serotype belonging to the recently identified HRV-C species  
are associated with more severe respiratory illness (Xiang et al 2008). Currently there are  
additional strains that have been added to the previous four subgroup namely subgroup A, B, 
C,  uncharacterised clade D which is found to be part of the HRV-A serotype with over 150 
strains of human rhinovirus (Lee  et al 2007; Palmenberg et al 2009). The newly discovered 
HRV-C species was implicated as an important cause of febrile illness, wheezing episodes and 
asthmatic exacerbations in hospitalized children (Lau et al 2007). Using multiplex PCR assays, 
rhinovirus was identified in 59.7% of 181 nasopharyngeal aspirate samples in children less 
than 2 years of age with respiratory illness (Lee et al 2007).  
 
2.4.2  Clinical significance 
Rhinovirus was initially isolated from individuals with common colds in 1956. Over the past 
50 years advances in molecular techniques, have improved the characterization of the clinical 
spectrum of rhinovirus illness. HRV has been associated with medically significant illness’ 
including acute otitis media, sinusitis and bronchiolitis (Mäkelä et al 1998; Choi et al 2006; 
Revai et al 2007). Lower respiratory tract infection due to HRV has also been associated with 
a triggering of asthmatic exacerbation in school-aged children (Johnston et al 1995; Lau et al 
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2007), acute exacerbation of cystic fibrosis (Rakes et al 1999) and otitis media (Moore et al 
2010 ). Rhinovirus has been shown to be present in asymptomatic patients (Moore et al., 
2010) and it has been implicated as an underlying cause of illness in both symptomatic and 
asymptomatic individuals (van Gageldonk-Lafeber et al 2005). In clinical studies, HRV 
infections have been associated with an impaired interferon response, which can enhance 
viral replication in patients with asthma (Jartti  and Korppi 2011). 
 
The prevalence of HRV in children with respiratory illness in developing countries is 
comparable with that of respiratory syncytial virus (RSV) in children less than 5 years. HRV 
was identified in 28% and RSV in 23% of Vietnamese children less than 5 years old with acute 
respiratory tract infections (Yoshida et al 2010). Similarly, Nascimento-Carvalho identified 
HRV in 21% and RSV in 15% of children hospitalized for community acquired pneumonia in 
Brazil (Nascimento-Carvalho et al 2008). In Kenya the prevalence of HRV in children less than 
5 years of age hospitalized for respiratory symptoms and fever was 84% of which 26% 
belonged to the recently identified group HRVC, 55% group HRV-A and 3% group HRV-B 
(Miller et al 2009). The latter study suggested that infections with HRV-C resulted in more 
severe illness with increased supplementary oxygen requirement in children infected with 
HRV-C compared to children infected with HRV-A alone. These studies suggest an important 
role for HRV as a possible cause of respiratory illness in children from developing countries. 
Similarly, in the USA the prevalence was of HRV in children under 5 years of age hospitalized 
with acute respiratory illness or fever was 16% (167 of 1052 episodes), of which subgroup 
characterization showed 43.5% to be HRV-A, 4.1% HRV-B and 52.4% HRV-C. Children with 
HRV-C were more likely to be diagnosed with asthma (Miller et al 2009). HRV has been 
detected in asymptomatic patients, these patients are regarded as those who are in 
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incubation period before symptoms are revealed, those that have viral particles and in which 
genetic material which is still detectable after infection has passed (Peltola et al 2004). 
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Table 2.4:  Clinical studies on Human Rhinovirus in children  
 
RTI : respiratory tract infection 
ARTI:  acute respiratory tract infection 
LRTI : lower respiratory tract infection 
URTI: upper respiratory tract infection 
 
Reference Study 
site 
Study 
Year 
n Illness 
description 
Prevalenc
e of HRV 
Age in 
years 
Co-
infection 
(Lee et al 
2007) 
USA  99-01 26  RTIs 59.6% <1 28 co-
infections 
with at 
least one 
other virus 
(Lau et al 
2007) 
China 04-05 1200  LRTIs & 
URTIs 
1.16%  
 
2 
months- 
3 yrs 
2 HMPV 
(Xiang et 
al 2008) 
China 07 258  LRTIs 5.5%  ≤15 1 RSV-
HCoV-NL63, 
7 RSV and 
3HPIV 
(Yoshida 
et al 2010) 
Vietnam 07-08 958  Acute RTIs 28%  ≤5 Not given 
(Miller et 
al 2009) 
 Kenya 
 
07 1468  RTIs &/or 
fever 
33%  <5 110 RSV, 17 
HMPV, 1 
Influ A 
(Miller et 
al 2009) 
USA, 
New 
York,  
01-03 1052  Acute  RTIs 
&/or fever 
16%  <5 2 RSV, 0.94 
HMPV, 0.62 
Influ, 0.62 
HPIV 
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Respiratory viruses have been implicated in the etiology of pneumonia and lower respiratory tract 
infections. Previous studies have shown that respiratory viruses contribute to bacterial infections by 
viral destruction of epithelium, viral upregulation of bacterial adhesion molecules such as (PAF) 
platelet-activating factor receptor and the effect of viral neuraminidase on bacterial adhesion (Madhi 
et al 2004; Peltola et al 2004). Respiratory viruses including rhinovirus have been implicated in 
increasing pneumococcal adherence to the epithelial cells (Ishizuka et al 2003). Pneumococcal 
conjugate vaccines have been shown to induce opsonophagocytic antibodies thus preventing 
acquisition of new pneumococcal serotype during upper respiratory tract infection (Madhi et al 
2004). However, viral susceptibility associated with pneumococcal pneumonia occurs during seven 
days before the pneumococcal capsule-induced antibody response and maybe a result of depletion 
of pneumococcal-capsular-antibody specific B cells by the vaccine before opsonophagocytic 
antibodies can develop (Klugman et al 2003). Vaccines provide useful tools to elucidate the roles of 
bacteria and respiratory viruses. PCV-9 prevented 31% of pneumonias associated with any of seven 
respiratory viruses in children in hospital, by preventing superimposed bacterial infections (Madhi et 
al 2004). 
 
The aim of the study was to reveal prevalence of newly discovered respiratory viruses in children 
whom had been hospitalized for lower respiratory tract infection. 
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2.5  Study objectives 
 
 
1. To establish an in-house multiplex PCR for the identification of select respiratory viruses. 
2. To identify, and determine the prevalence of the studied viruses in HIV-uninfected 
children hospitalized for lower respiratory tract infection. 
3. To describe the clinical symptoms during the course of LRTI in the children in whom the 
viruses were identified. 
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Chapter 3:  Methods 
 
 
3.1  Study population  
This study involved a retrospective analysis of nasopharyngeal aspirate (NPA) samples 
obtained in children hospitalized for lower respiratory tract infections. The children had been 
enrolled as part of a phase III double blind, placebo controlled trial of a 9-valent 
pneumococcal conjugate vaccine (PCV-9) in Soweto, South Africa (Klugman et al 2003). The 
PCV formulation included serotypes 1, 5, 4, 6B, 9V, 18C, 19F and 23F which were 
independently conjugated to the non-toxic diphtheria toxoid molecule (also known as cross 
reactive molecule-197; CRM197). In this trial 39,836 children were enrolled from March 1998 
to October 2000 and randomized to receive either three doses of PCV-9 or placebo. Overall 
18, 245 received all three doses of study-vaccine and 18,268 received all three doses of 
placebo as per randomization.  
 
The study-cohort was monitored for hospitalization for LRTI through daily surveillance 
conducted at Chris Hani Baragwanath hospital for the duration of the trial from March 1998 
to October 2005. The first dose of study-vaccine was administered at a mean age (±SD) of 6.6 
(±1.2) weeks, second dose at 11.2 (±2.5) weeks and the third dose at 15.9 (±3.8) weeks of 
age. No booster dose of PCV was given. All hospitalized children were evaluated clinically by 
one of the study doctors who used a standardized form for documenting clinical signs and 
symptoms. Children with a LRTI had nasopharyngeal aspirates collected which were analysed 
for selected respiratory viruses by immunofluorescence assays or by nested PCR SA (Madhi 
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et al 2004). Testing was initially undertaken at the National Institute of Virology, South Africa 
and subsequently as from February 2000 at the Respiratory Meningeal Pathogens Unit 
(RMPRU). The method of NPA collection and archiving of samples in viral transport medium 
has been previously described (Madhi et al 2004). Initial testing of the samples included 
testing for RSV, Influenza A and B virus, Parainfluenza viruses type 1-3 and Adenovirus using 
immunofluorescence assays (Madhi et al 2004). Aliquots of NPA samples tested at the 
RMPRU were archived at -70°C. These archived samples were subsequently tested for human 
metapneumovirus by nested RT-PCR as previously detailed by (Madhi et al 2005). 
 
The present study involved further evaluation of available archived NPA samples from study-
participants who were hospitalized for LRTI from February 2000 onward. For the purposes of 
this exploratory study testing of samples was limited to samples obtained from HIV-
uninfected children less than two years of age for the presence of emerging respiratory 
viruses in children hospitalized for LRTI. The study focused on HIV-uninfected children based 
on an earlier study which indicated that established respiratory viruses such as RSV, influenza 
viruses, PIV and adenovirus were identified less commonly in HIV-infected (15.7%) than HIV-
uninfected children (34.8%, p<0.0001) when hospitalized for LRTI (Madhi et al 2000).  
 
3.2  Study-specific definitions 
The clinical definition for LRTI, pneumonia and bronchiolitis used in this study are the same 
as previously described by Madhi et al (2005). Briefly, LRTI was defined as any episode with 
clinical diagnosis of pneumonia or bronchiolitis done by a study physician, irrespective of 
symptoms found by clinical examination or chest radiography (CXR) features. Children with 
LRTI were categorized as having clinical pneumonia if they had evidence of alveolar 
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consolidation on CXR (CXR-AC) or if they fulfilled the clinical diagnosis of LRTI without wheeze 
on chest auscultation but had rales and/or bronchial breathing. Children were categorized as 
having bronchiolitis in the presence of wheezing on chest auscultation performed by one of 
the study doctors and in the absence of documented alveolar consolidation on chest 
radiograph or bronchial breathing on chest wall auscultation. CXR-AC was evaluated on the 
basis of criteria agreed on by the Vaccine Trialist Working Group, coordinated by the WHO 
(Cherian T 2005).  
  
3.3  Sample extractions and PCR optimization and screening 
Internal Control and sample extraction procedure 
Archived NPA samples were thawed overnight at 4°C. Samples were briefly vortexed for 15 
seconds and centrifuged at 2000 g for 5 minutes. A sample volume of 200µL was spiked with 
internal controls prior to extraction. The internal controls were used to monitor the 
efficiency of the nucleic acid extraction, reverse transcriptase reaction, and amplification of 
target nucleic acids. The selected internal controls in our study were the Newcastle Disease 
Virus (NDV) a RNA virus and the Lambda phage, a DNA virus internal control. Lambda phage 
was spiked at a concentration of 103 plaque forming units (pfu) per sample, which yielded an 
average cycle threshold (CT) of 20-35 cycles. NDV spike concentration was 104 copies of viral 
particle/sample, which produced average CT of 20-25 cycles (Table 4.1 in Results section). 
Controls with a high cycle threshold value (37-40) were considered negative result, therefore 
if either DNA control was had a low threshold value RNA control was used to validate the 
extraction, reverse transcription reaction and amplification reaction. Nucleic acids of spiked 
samples were extracted with the Easymag nucleic acid extraction robot (Biomerieux, France) 
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and the off-board extraction protocol was selected with the following variable parameters: 
volumes of sample was 1000µl (200µl of sample and 800µl of lysis extraction buffer), after 
lysis each sample was transferred to a vessel and 125µl of magnetic silica was added, finally 
55 µl were eluted in the extraction kit elution buffer and stored at -70°C for further analysis.  
 
Control DNA  
Positive control DNA was obtained as a gift from Dr. Rossen for the viruses HBoV, WUPyV, 
KIPyV, HRV, HCoV-229E, HCoV-OC43 and HCoV-NL63. The controls were quantified to have 
100,000 copies per reaction and a 10-fold dilution of this stock was used routinely as positive 
controls for all the PCR reaction. For the PCR reactions to detect HCoV-HKU1 viruses, and for 
which no positive control DNA was available, the control was obtained from clinical samples. 
Briefly, clinical samples were screened for a positive reaction with a generic amplification 
protocol and published primer sets followed by confirmation of the fragment length by gel 
electrophoresis. The positive sample was used as target material to further optimize the PCR, 
and as positive controls for subsequent reactions. The range of CT for positive control 
samples for HRV was 25-29 cycles, 18-25 cycles for HBoV, 30-35 cycles for KIPyV, 30-35 cycles 
for WUPyV, 20-29 cycles for HCoV-NL63, for HCoV-HKU1 was 20-29, HCoV-OC43 was 20-29 
and HCoV-229E was 20-29 cycles. 
 
PCR procedure 
Complementary DNA was synthesized with the Multiscribe kit without RNAse inhibitor 
(Applied Biosystems, SA). Reverse transcription-PCR reactions were performed with 10µl of 
sample eluted from the Easymag nucleic acid extraction machine and 10µL of master mix 
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according to the manufacturer’s recommendations (Appendix: Figure 8.2). The cycling 
conditions were as follows: 25°C for 10min, 37°C for 2hrs and 85°C for 5sec (Appendix: Figure 
8.3). Real time reactions were performed in a total of 25µl with 12.5µl of 2 x Taqman 
universal polymerase chain reaction master mix with AmpErase-Uracil-N-glycosylase (UNG) 
(Applied Biosystems, SA). Contamination and false positives from high copy number DNA was 
eliminated by the AmpErase-Uracil-N-glycosylase (UNG) enzyme present in the reaction mix, 
which is active during the first incubation step of 50°C for 2min. During PCR dUTP substitute’s 
dTTP in the PCR reaction, the enzyme UNG which is present in the master mix degrades 
Uracil-containing DNA from previous reactions that may be present in the PCR reaction. In 
this way products from previous PCR or non-specific or misprimed products produced prior 
to amplification of target product are eliminated. Hence the initial incubation step of the 
real-time PCR is the UNG activation which is followed by deactivation at 95°C for 10min. 
Reactions were performed with 5µL of cDNA for detecting RNA viruses and 5µL of total 
nucleic acid for detecting DNA viruses. Real time cycling conditions were as follows: 1cycle of 
50°C for 2min, 1 cycle of 95°C for 10min, 40 cycles of 95°C for 15s and 60°C for 1min. The 
primer concentrations for each duplex reaction are shown in Table 3.4.  
 
The optimized cycle thresholds for each respiratory virus control are used as reference for a 
sample with high DNA concentration, hence a virus with a lower CT indicates that they are 
detected early in PCR and have a high DNA concentration. Hence the optimal cycles observed 
above were used as a guideline to show qualitative results for samples with high DNA 
concentration. Samples with a low DNA concentration are detected later in the PCR and 
these samples have a high CT. Hence controls with a low DNA concentration are used as a 
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reference for qualitative results for samples with low DNA concentration. Negative results 
were deduced by the software as Not Detected. 
 
Primer and probe optimizations and detection limits of the assay 
Table 3.1 shows the primer and probe sequences, target gene and published reference for 
each targeted virus. Virus specific primer and probe sequence combinations were based on 
previously published sequences and the target regions represented highly conserved regions 
for each virus. Primer and probe optimizations were performed with the ABI 7500 Real Time 
PCR machine and Taqman Universal PCR Master Mix. Primer and probe for the internal 
controls were optimized using internal control DNA and cDNA. Positive controls were used to 
optimize the primer and probe concentrations for the newly discovered respiratory viruses. 
The primer dilutions were prepare in the reaction plates, as per the dilution matrix as 
indicated in Table 3.2. The optimal primer concentration of forward and reverse primers was 
selected as being the lowest concentration at which there was no effect on the sensitivity of 
the reaction as determined by the CT and delta reaction using the linear phase of the 
amplification curve at the threshold. These primer limiting reaction conditions resulted in a 
primer set that would amplify the target with maximum sensitivity, but would not reach 
saturation, and thus allow a second target to amplify as a multiplex within the same reaction. 
PCR optimizations were done and the level of duplex was achieved with pairing of two 
viruses at a time, the 5 pairs of viruses were detected simultaneously on one plate. The 
results of the primer matrixes and optimizations are shown in the Appendix, (Tables 8.3-8.6). 
Duplex reactions were paired in accordance with the type of nucleic acid present in the virus, 
that is RNA viruses were co-paired separately from DNA viruses. The following multiplex pairs 
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reactions were performed: HCOV-NL63 and HCoV-OC43; HCoV-HKU and HRV; WUPyV and 
KIPyV; NDV RNA control and HCoV-229E and HBoV and Lambda DNA control. 
These pairings were validated to determine whether there was any loss of sensitivity in the 
presence of a second target, by performing a template dilution matrix of the two target 
DNA’s, as shown in Table 3.3. Duplexed primer pairs were selected if the paired combination 
met the following criteria: there was no loss of sensitivity or significant change in CT when 
both targets are present in the same reaction at any concentration, compared to a single 
target, and there was no cross reactivity caused by the multiplex. The results of these 
matrixes are shown in the Appendix, (Tables 8.7-8.11).  
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Table 3.1: Primer and probes sequences used to detect respiratory viruses of interest 
Primer Gene Reference Sequence 
HCoV-OC 
forward 
N-gene 
(van Elden et al 
2004) 
CGA TGA GGC TAT TCC GAC TAG GT 
HCoV-OC 
reverse 
N-gene 
(van Elden et al 
2004) 
CCT TCC TGA GCC TTC AAT ATA GTA ACC 
HCoV-OC Probe N-gene 
(van Elden et al 
2004) 
5’ FAM-TCC GCC TGG CAC GGT ACT CCC T-TAMRA 3’ 
HCoV-229E 
forward 
N-gene 
(van Elden et al 
2004) 
CAG TCA AAT GGG CTG ATG CA 
HCoV-229E 
reverse 
N-gene 
(van Elden et al 
2004) 
AAA GGG CTA TAA AGA GAA TAA GGT ATT CT 
HCoV-229E 
Probe 
N-gene 
(van Elden et al 
2004) 
5’VIC-CCC TGA CGA CCA CGT TGT GGT TCA-TAMRA 3’ 
HCoV-NL 
forward    
N-gene 
(Fouchier et al 
2004) 
GCG TGT TCC TAC CAG AGA GGA 
HCoV-NL 
reverse     
N-gene 
(Fouchier et al 
2004) 
GCT GTG GAA AAC CTT TGG CA 
HCoV-NL Probe N-gene 
(Fouchier et al 
2004) 
5’ VIC-ATG TTA TTC AGT GCT TTG GTC CTC GTG AT-TAMRA 3’ 
HKU1 forward N-gene In house CGC CTG GTA CGA TTT TGC C 
HKU1 reverse N-gene In house GAA CGA TTA TTG GGT CCA CGT G 
HKU1 Probe N-gene In house 5’ VIC- TGTTGA AGG CTC AGG AAG GTC TGC TTC TAA-TAMRA 3’ 
HBoV forward NP1 gene Dr. J. Rossen GGA AGA GAC ACT GGC AGA CAA 
HBoV reverse NP1 gene Dr. J. Rossen GGG TGT TCC TGA TGA TAT GAG C 
HBoV Probe NP1 gene Dr. J. Rossen 5’ FAM- CTG CGG CTC CTG CTC CTG TGA T -TAMRA 3’ 
HRV forward 5’ UTR Dr. J. Rossen,  GCC TGC GTG GCT GCC 
HRV reverse 5’ UTR Dr. J. Rossen,  CCT GCG TGG CGG CC 
HRV forward 5’ UTR Dr. J. Rossen ACG GAC ACC CAA AGT AGT TGG T 
HRV reverse 5’ UTR Dr. J. Rossen ACG GAC ACC CAA AGT AGT CGG T 
HRV Probe 5’ UTR Dr. J. Rossen 5’ FAM- TCC GGC CCC TGA ATG TGG CTA A -TAMRA 3’ 
HRV Probe 5’ UTR Dr. J. Rossen 5’ FAM- TCC GGC CCC TGA ATG CGG CTA A -TAMRA 3’ 
HRV forward 5’ UTR Dr. J. Rossen,  GCC TGC GTG GCT GCC 
WU forward Gp5 Dr. J. Rossen GGC ACG GCG CCA ACT 
WU reverse Gp5 Dr. J. Rossen CCT GTT GTA GGC CTT ACT TAC CTG TA 
WU Probe Gp5 Dr. J. Rossen 5’ FAM-TGC CAT ACC AAC ACA GCT GCT GAG C 3’ 
KI forward NTR Dr. J. Rossen ACC TGA TAC CGG CGG AAC T 
KI reverse NTR Dr. J. Rossen CGC AGG AAG CTG GCT CAC 
KI Probe NTR Dr. J. Rossen 5’ VIC-CCA CAC AAT AGC TTT CAC TCT TGG CGT GA 3’ 
Dr John WA Rossen, St Elisabeth Hospital, Laboratory of Medical Microbiology and Immunology, 
Tilburg, Netherlands. Phone: + 31 (0)13 5393488. Fax: + 31 (0)13 5441264, john.rossen@gmail.com 
and j, rossen@elisabeth.nl 
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Table 3.2: Primer matrix for all viruses 
Primers 
(uM c) 
1st dilution 
1.3uM 
2nd dilution 
0.6uM 
3rd dilution 
0.33uM 
4thdilution 
0.16uM 
5th dilution 
0.08uM 
6th dilution 
0.04uM 
1st dilution 
1.3Um 
1.3Fa/1.3Rb 1.3F/ 0.6R 1.3F/0.33R 1.3F/0.16R 1.3F/ 0.08R 1.3F/0.04R 
2nd dilution 
0.6uM  
0.6F/1.3R 0.6F/0.6R 0.6F/0.33R 0.6F/0.16R 0.6F/0.08R 0.6F/0.04R 
3rd dilution 
0.33uM 
0.33F/1.3R 0.33F/0.6R 0.33F/0.33R 0.33F/0.16R 0.33F/0.08R 0.33F/0.04R 
4th dilution 
0.16uM 
0.16F/1.3R 0.16F/0.6R 0.16F/0.33R 0.16F/0.16R 0.16F/0.08R 0.16F/0.04R 
5th dilution 
0.08uM 
0.08F/1.3R 0.08F/0.6R 0.08F/0.33R 0.08F/0.16R 0.08F/0.08R 0.08F/0.04R 
6th dilution 
0.04uM 
0.04F/1.3R 0.04F/0.6R 0.04F/0.33R 0.04F/0.16R 0.04F/0.08R 0.04F/0.04R 
a forward primer 
b Reverse primer 
c Molar concentration 
 
Table 3.3: DNA matrixes for all viruses 
 1
st
 dilution 2
nd
 dilution 3
rd
 dilution 4
th
 dilution 5
th
 dilution 
 1
st
 dilution 1
st 
/1
st
 2
nd
 /1
st
 3
rd
 /1
st
 4
th
 /1
st
 5
th
 /1
st
 
 2
nd
 dilution 1
st
/2
nd
 2
nd
 /2
nd
 3
rd
 /2
nd
 4
th
 /2
nd
 5
th
 /2
nd
 
 3
rd
 dilution 1
st
/ 3
rd
  2
nd
 /3
rd
   3
rd
 /3
rd
   4
th
 /3
rd
   5
th
 /3
rd
  
 4
th
 dilution 1
st
/4
th
 2
nd
 /4
th
 3
rd
 /4
th
 4
th
 /4
th
 5
th
 /4
th
 
 5
th
 dilution 1
st
/ 5
th
  2
nd
 /5
th
   3
rd
 /5
th
   4
th
 /5
th
   5
th
 /5
th
  
1st dilution is the highest dilution from original stock diluted 10X, followed by 2nd dilution which is 
diluted 100X, 3rd is diluted 1000X, 4th is diluted 10000X and 5th is diluted 1000000X 
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Table 3.4: Optimized primer-pairs concentration used in detected target 
respiratory viruses 
Primers-pairs  Concentrations (uM) Forward Reverse Probe 
DNA Viruses HBoV 0.2 0.2 0.3 
  Lambda 0.32 0.08 0.3 
  Polyomavirus-WU 0.8 0.4 0.3 
  Polyomavirus-KI 0.8 0.2 0.3 
RNA Viruses HCoV-229E 0.2 0.2 0.3 
  NDV 0.16 0.08 0.3 
  HCoV-OC43 0.2 0.2 0.3 
  HCoV-NL63 0.2 0.2 0.3 
  HCoV-HKU1 0.3 0.3 0.3 
  Rhinovirus 0.2 0.2 0.3 
 
 
3.4  Statistical Analysis 
Data were analyzed using STATA (version 8.0; Stata Corp). Proportions were compared using 
the χ2 test and the Fisher’s exact test if the expected cell value was < 5 observations, an 
alpha ≤0.05 was considered significant. Due to a low frequency of positive coronavirus-229E, 
the virus was excluded from some of the analysis 
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Chapter 4:  Results 
 
4.1  Sensitivity and Specificity  
Using a serial dilution series the limits of detection were determined for each virus. Detection 
limits are shown in Table 4.1, the detection limits for all the viruses were less than 100 
copies/ reaction with exceptions for HRV , WUPyV and KIPyV that were less than 1000 
copies/ reaction. In addition controls were paired with each other to show specificity 
(Appendix Tables 8.7 to 8.12). 
Table 4.1:  Limits of detection of respiratory viruses 
Dilution 
series  
1:10 (105) 1:100 (105) 1:1000(105)   1:10000(105)  1:100000 (105)  
HBoV 18# 20 24 29 ND* 
HRV 25 27 30 ND ND 
WUPyV 30 34 36 ND ND 
KIPyV 30 33 37 ND ND 
HCoV-NL63 20 24 26 31 ND 
HCoV-HKU1 20 a 24 26 29 ND 
HCoV-OC43 20 23 26 29 ND 
HCoV-229E 21 25 28 31 ND 
Lambda 18 20 22 24 ND 
NDV 20 24 29 33 ND 
*ND Not detected= negative 
#Cycle threshold value=positive 
(10E5) concentration given with DNA extracts from Dr. Rossen with exception to HCoV-HKU 1 
a: cycle threshold obtained from patient sample HCoV-HKU 1 from our laboratory 
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4.2 Demographic features of available and unavailable samples in LRTI episodes  
To determine whether there was any sampling bias between the NPA samples that were 
available for testing from the original study and the samples we used, a selection of 
demographic and clinical features of the LRTI episodes from the tested samples were 
compared to those that were not tested. Overall, 895 (57.2%) of 1565 nasopharyngeal 
aspirates from children under two years of age hospitalized for LRTI, from February 2000 
onward, were available for testing (Table 4.2). Samples unavailable for testing were collected 
from younger children compared to the samples that were available for testing (9.9 months 
±6.41 (±SD) vs. 11.8 months ±6.50, respectively; p<0.0001), were associated with a lower 
mean temperature on admission (37.2oC vs. 37.4oC, respectively; p=0.035) and were more 
likely to be associated with wheezing (60.4% vs. 54.6%; p=0.022). 
Table 4.2:  Selected features of LRTI episodes for which samples were tested compared 
to those in which samples were unavailable for testing in HIV-uninfected 
children less than two years of age 
Demographic features 
 
Samples tested 
N=895 
Samples not tested 
N=670 
P 
value 
 
% of total 57.19 42.81  
Age in months ± SD 11.83±6.50 9.91±6.41 <0.001 
Female (%) 42.5 42.8 0.88 
Mean temperature in °C ±SD 37.43±2.07 37.18±0.77 0.035 
Bronchial breathing n (%) 30 (3.4) 25 (3.8) 0.65 
Wheezing n (%) 488 (54.6 401 (60.4) 0.022 
C repitations/ rales n (%) 541 (60.5) 372 (56.0) 0.08 
Mean Respiration Rate per minute ±SD 49.94±19.82 51.69±19.74 0.08 
Mean weight in Kg ±SD 9.27±3.44 9.14±5.15 0.73 
Pneumonia n (%) 464 (51.8) 332 (49.6) 0.11 
Bronchiolitis n (%) 431 (48.2) 338 (50.4) 0.11 
ICU Admission (%) 12 (1.3) 9 (1.3) 0.96 
Deaths due to LRTI (%) 8 (0.89) 13 (1.9) 0.08 
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4.3  The prevalence of identifying the studied viruses in children hospitalized for LRTIs 
The overall prevalence of the newly studied respiratory viruses, stratified by PCV vaccination 
status, and prevalence thereof in clinical syndromes of bronchiolitis and pneumonia are 
shown in Table 4.3 to Table 4.5. For comparison purposes, Tables 4.3, 4.4 and 4.5 also 
illustrates the prevalence of other previously studied respiratory viruses including RSV, PIV 1-
3, influenza A/B virus, hMPV and adenovirus in the group of children for whom samples were 
available for evaluation in this study. The total prevalence of the viruses in children with LRTI 
were 33.2% for HRV, 21.2% for HBoV, 16.1% for WUPyV, 10.1% for HCoV-OC43, 7.0% for 
KIPyV, 3.2% for HCoV-NL63, 2.6% for HCoV-HKU-1, and 0.6% for HCoV-229E.   
 
Differences by PCV-vaccination status in the probability of identification of a newly studied 
viruses included a higher frequency of HBoV (24.2% vs. 18.2%; p=0.028) ,and HRV (36.7% vs. 
29.5%; p=0.023) in children vaccinated with PCV compared to placebo recipients (Table 4.3). 
Conversely, viruses identified more frequently in children who received placebo compared to 
PCV-recipients included WUPyV (20.2% vs. 12.1%, p<0.0001), HCoV-OC43 (14.1% vs. 10.1%; 
p<0.0001) and HCoV-HKU1 (14.1% vs. 2.6%; p<0.0001) and KIPyV (10.0% vs. 4.2%; p<0.0001).  
At least one virus was identified in 82.2% LRTI episodes, which occurred with a higher 
frequency in placebo- (85.2%) than PCV-recipients (79.3%; p=0.021). In addition, concurrent 
infection by two viruses were identified in 59.3% overall; and were also more common in the 
placebo (68.0%) than in the PCV (51.0%; p<0.0001) group. Multiple co-infections with three 
or more viruses were identified in 16.7% of all LRTI episodes, and likewise also more 
commonly identified in placebo (21.1%) compared to PCV-recipients (12.3%; p<0.0001) 
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Table 4.4 indicates the prevalence of studied viruses in children with bronchiolitis. In these 
children at least one virus was identified in 85.2% of episodes. The overall prevalence of 
identifying the studied viruses were 33.8% for HRV, 33.4% for WUPyV, 22.3% for HBoV,  
11.1% for HCoV-OC435.3% for KIPyV, , 2.3% for HCoV-NL63, 1.9% for HCoV-HKU1 and 0.4% 
for HCoV-229E. Viruses more commonly identifying in placebo compared to PCV recipients 
were WUPyV (20.0% vs. 12.3%, respectively; p=0.029) and HCoV-OC43 (15.9% vs. 7.2%, 
respectively; p=0.004). Viruses more commonly identifying in PCV recipients compared to 
placebo was HCoV-HKU1 (2.5% vs. 2.1; p=0.015) There was a higher probability of identifying 
three or more concurrent viruses among placebo (21.1%) compared to PCV recipients 
(13.6%; p=0.04). 
 
The prevalence of the newly studied viruses in children with clinical pneumonia was 30.8% 
for HRV, 20.3% for HBoV, 16.4% for WUPyV, 9.1% for HCoV-OC43, 8.6% for KIPyV, 4.1% for 
HCoV-NL63, 3.2% for HCoV-HKU1 and 0.6% for HCoV-229E; Table 4.5. A total of 79.5% clinical 
pneumonia episodes were identified to be associated with at least one virus, including those 
viruses which had been previously studied in these samples. The prevalence of individual 
viruses was greater in placebo than PCV recipients for WUPyV (20.4% vs. 11.9%, respectively; 
p=0.013), KIPyV (12.7% vs. 4.1%, p=0.001) andHCoV-HKU1 (5.3% vs. 0.9%, p=0.008). 
Conversely, HCoV-OC43 was identified more frequently in children who received PCV (5.0%) 
compared to placebo recipients (2.7%; p=0.004). There were no differences in prevalence of 
HBoV, HCoV-NL63 and HRV between placebo and PCV recipients hospitalized for clinical 
pneumonia. There was, however, a higher frequency of identifying at least one virus in the 
placebo (88.5%) than PCV recipients (74.0%; p=0.005). Overall, two concurrent viruses were 
identified in 60.3% of clinical pneumonia cases, co-infections were also more common in 
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placebo (71.8%) compared to PCV recipients (47.5%; p<0.0001). Similarly, 16.4% of all clinical 
pneumonia episodes were associated with identification of at least three viruses, which also 
occurred more frequently in placebo (21.2%) compared to PCV recipients (11.0%; p=0.003). 
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Table 4.3: Prevalence of newly emerging viruses and previously studied viruses in 
children hospitalized for LRTI 
Virus detected 
Total N=895 
N,  [%; 95% CI] 
Placebo N=440 
N,  [%; 95% CI] 
Vaccine N=455 
N,  [%; 95% CI] 
p-value1 
HBoV 
190 
[21.2; 18.6, 24.1] 
80 
[18.2; 14.7, 22.1] 
110 
[24.2; 20.3, 28.4] 
0.028 
WUPyV 
144 
[16.1; 13.7, 18.7] 
89 
[20.2; 16.6, 24.3] 
55 
[12.1; 9.2, 15.4] 
0.001 
KIPyV 
63 
[7.0; 5.5, 8.9] 
44 
[10; 7.4, 13.2] 
19 
[4.2; 2.5, 6.4] 
0.001 
HCoV-NL63 
29 
[3.2; 2.2, 4.6] 
13 
[3; 1.6, 5] 
16 
[3.5; 25.6] 
0.86 
HCoV-HKU1 
23 
[2.6; 1.6, 3.8] 
20 
[4.5; 2.8, 6.9] 
3 
[0.1; 0.01, 1.2] 
<0.0001 
HCoV-OC43 
90 
[10.1; 8.2, 12.2] 
62 
[14.1; 11, 17.7] 
28 
[6.2; 4.1, 8.8] 
<0.0001 
HCoV-229E 
5 
[0.6; 0.2, 1.3] 
4 
[0.9; 0.2, 2.3] 
1 
[0.2; 0.01, 1.2] 
0.18 
HRV 
297 
[33.2; 30.1, 36.4] 
130 
[29.5; 25.3, 34.1] 
167 
[36.7; 32.3, 41.3] 
0.023 
RSV2 
209  
[23.4; 20.6, 26.3] 
100 
[23; 19, 27] 
109 
[24; 20.1, 28.2] 
0.66 
Influenza A/B2 
48 
[5.4; 3.98, 7.1]  
23  
[5.2;3.3, 7.7] 
25 
[5.5; 3.6, 8.0] 
0.86 
Para influenza 1-
32 
36 
[4.0; 2.8, 5.5] 
15 
[3.4; 1.9, 5.6] 
21 
[4.6; 2.9, 6.9] 
0.36 
Adenovirus2 
22 
[2.5; 1.5, 3.7] 
13  
[2.9; 1.6, 4.9] 
9 
[1.97; 0.9, 3.7] 
0.35 
hMPV2 
82 
[9.2; 7.4, 11.2] 
49 
[11.1; 8.4, 14.5] 
33 
[7.3; 5.0, 10.0] 
0.044 
At least 1 virus 
identified 
736 
[82.2; 79.6, 84.7] 
375 
[85.2; 81.6, 88.4] 
361 
[79.3; 75.3, 82.9] 
0.021 
2 viruses 
identified  
531 
[59.3; 56.0, 62.6] 
299 
[68; 63.4, 72.3] 
232 
[51; 46.3, 55.7] 
<0.0001 
≥3viruses 
identified 
149 
[16.7;14.3, 19.3] 
93 
[21.1;17.4, 25.3] 
56 
[12.3; 9.4, 15.7] 
<0.0001 
1 p-values show a comparison between placebo and vaccine group 
2Indicate previously detected respiratory viruses from the samples tested in this study 
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Table 4.4: Prevalence of newly emerging viruses and previously studied viruses in 
children hospitalized for bronchiolitis 
Virus detected 
Total N=431 
N,  [%; 95% CI] 
Placebo N=195 
N,  [%; 95% CI] 
Vaccine N=236 
N,  [%; 95% CI] 
p-value1 
HBoV 
96 
[22.3; 18.4, 26.5] 
36 
[18.5; 13.3, 24.6] 
60 
[25.4; 20, 31.5] 
0.08 
WUPyV 
68 
[33.4; 29, 38.1] 
39 
20.0 ]14.6, 26.3] 
29 
[12.3; 8.4, 17.2] 
0.029 
KIPyV 
23 
[5.3; 3.4, 7.9] 
13 
[6.7; 3.6, 11.1] 
10 
[4.2; 2.1, 7.7] 
0.26 
HCoV-NL63 
10 
[2.3; 1.1, 4.2] 
4 
[2.1; 0.6, 5.2] 
6 
[2.5; 0.9, 5.5] 
1.00 
HCoV-HKU1 
8 
[1.9; 0.8, 3.6] 
7 
[3.6; 1.5, 7.3] 
1 
[0.4; 0.01, 2.3] 
0.015 
HCoV-OC43 
48 
[11.1; 8.3, 14.5] 
31 
[15.9; 11.1, 21.8] 
17 
[7.2; 4.3, 11.3] 
0.004 
HCoV-229E 
2 
[0.5; 0.1, 1.7] 
1 
[0.5; 0.01, 2.8] 
1 
[0.4; 0.01, 2.3] 
0.89 
HRV 
154 
[35.7; 31.2, 40.5] 
62 
[31.8; 25.3, 38.8] 
92 
[39; 32.7, 45.5] 
0.12 
RSV2 
117 
[27.2; 23.0, 31.6] 
48 
[24.6; 18.7, 31.3] 
69 
[29.2; 23.5, 35.5] 
0.28 
Influenza A/B2 
19 
[4.4;2.7, 6.8] 
6 
[3.1; 1.1, 6.6] 
13 
[5.5; 2.9, 9.2] 
0.22 
Para influenza 1-
32 
18 
[4.2; 2.5, 6.5] 
6 
[3.1; 1.1, 6.6] 
12 
[5.1; 2.7, 8.7] 
0.30 
Adenovirus2 
9 
[2.1; 0.1, 3.9] 
6 
[3.1; 1.1, 6.6] 
3 
[1.3; 0.3, 3.7] 
0.19 
hMPV2 
43 
[9.9; 7.3, 13.2] 
25 
[12.8; 8.5, 18.3] 
18 
[7.6; 4.6, 11.8] 
0.07 
At least 1 virus 
identified 
367  
[85.2; 88.4] 
168  
[86.2;80.5, 90.7] 
199  
[84,3; 79.0, 88.7] 
0.59 
2 viruses 
identified  
251 
[58.2; 53.4, 62.9] 
123 
[63.1; 55.9, 69.9] 
128 
[54.2; 47.7, 60.7] 
0.06 
≥3viruses 
identified 
73 
[17; 13.5, 20.8] 
41 
[21.0; 15.5, 27.4] 
32 
[13.6; 9.5, 18.6] 
0.04 
1 p-values show a comparison between placebo and vaccine group 
2Indicate previously detected respiratory viruses from the samples tested in this study 
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Table 4.5: Prevalence of newly described viruses and previously studied viruses in  
 
children hospitalized for pneumonia 
 
Virus detected 
Total N=464 
N,  [%; 95% CI] 
Placebo N=245 
N,  [%; 95% CI] 
Vaccine N=219 
N,  [%; 95% CI] 
p-value1 
HBoV 
94 
[20.3; 16.7, 24.2] 
44 
[18; 13.4, 23.3] 
50 
[22.8; 17.4, 29] 
0.19 
WUPyV 
76  
[16.4; 13.1, 20.1] 
50 
[20.4; 15.5, 26] 
26 
[11.9; 7.9, 16.9] 
0.013 
KIPyV 
40 
[8.6; 6.2, 11.6] 
31 
[12.7; 8.8, 17.5] 
9 
[4.1; 1.9, 7.7] 
0.001 
HCoV-NL63 
19 
[4.1; 2.5, 6.3] 
9 
[3.7; 1.7, 6.9] 
10 
[4.6; 2.2, 8.2] 
0.63 
HCoV-HKU1 
15  
[3.2; 1.8, 5.3] 
13 
[5.3; 2.9, 8.9] 
2 
[0.9; 0.1, 3.3] 
0.008 
HCoV-OC43 
42 
[9.1; 6.7, 12.0] 
31 
[2.7; 8.8, 17.5] 
11 
[5; 2.5, 8.8] 
0.004 
HCoV-229E 
3 
[0.6; 0.1, 1.9] 
3 
[0 ; 0.0, 1.7] 
0 0.25 
HRV 
143 
[30.8; 26.6, 35.2] 
68 
[27.8; 22.2, 33.8] 
75 
[32.2; 28.0, 41.0] 
0.13 
RSV2 
92 
[19.8; 16.3, 23.8] 
52 
[21.2; 16.3, 26.9] 
40 
[18.3; 13.4, 24.0] 
0.43 
Influenza A/B2 
29 
[6.3; 4.2, 8.8] 
17 
[6.9; 4.1, 10.9] 
12 
[5.5; 2.9, 9.4] 
0.52 
Para influenza 1-32 
18 
[3.9; 2.3, 6.1] 
9 
[3.7; 1.7, 6.9] 
9 
[4.1; 1.9, 7.7] 
0.81 
Adenovirus2 
13  
[2.8; 1.5, 4.5] 
7 
[2.9; 1.2, 5.8] 
6 
[2.7; 1.0, 5.9] 
0.94 
hMPV2 
39 
[8.4; 6.0, 11.3] 
24 
[9.8; 6.4, 14.2] 
15 
[6.8; 3.9, 1.0] 
0.25 
At least 1 virus 
identified 
369  
[79.5; 75.6, 83.1] 
207  
[88.5; 79.3, 88.8] 
162  
[74; 67.6, 79.7] 
0.005 
2 viruses identified  
280 
[60.3; 55.7, 64.8] 
176 
[71.8; 65.8, 77.4] 
104 
[47.5; 40.7, 54.3] 
<0.0001 
≥3viruses identified 
76  
[16.4; 13.1, 20.1] 
52 
[21.2; 16.3, 26.9] 
24 
[11; 7.2, 15.8] 
0.003 
1 p-values show a comparison between placebo and vaccine group 
2Indicate previously detected respiratory viruses from the samples tested in this study 
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4.4 Respiratory viral co-infections in LRTI episodes 
Co-infections are defined as an infection of more than 2 viruses detected in one specimen. 
The viral co-infections of new respiratory viruses and older respiratory viruses were 
compared. in this context our results revealed a co-infection of more than 2 viruses detected 
from one specimen, hence the results in Tables 4.6, 4.7 and 4.8 show a higher number of co-
infections found in samples positive for each respiratory virus. For instance in WUPyV the 
number of children positive for WUPyV is a hundred and forty four (144) whereas the co-
infections observed is a hundred and sixty, thus indicating that children with WUPyV had 
more than one virus infection.  Overall higher viral co-infections in all three syndromes was 
observed for the HRV, WUPyV, HBoV and RSV. 
 
Table 4.6 details the prevalence of co-infection occurring in children with LRTI. The table 
describes the probability of co-infection to occur for each respiratory virus. From table 4.6 a 
number of significant differences in the detection of respiratory viruses was observed when 
comparing the co-infections to other viruses detected in a group of children with a 
respiratory virus. Comparing the different episodes of LRTI where HBoV was detected with 
another virus, co-infections with HRV were significantly more prevalent than the other co-
infections (p=0.027). Comparing detection of respiratory virus with another respiratory virus, 
the significant viral co-infection was WUPyV with HMPV (n=12; 8.3%; p=0.020), HRV (n= 42; 
29.2%; p value=0.045) and HCoV-OC43 (n=20, 13.9%, p=0.006). Eighty two percent of the 190 
LRTI episodes in which HBoV was identified were associated with co-infection with one of the 
other viruses. The top three most common viral co-infection with HBoV were HRV (n=50; 
26.3%), WUPyV (n=30; 15.8%) and RSV (n=17; 8.9%).  
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90% of 144 LRTI episodes in which WUPyV was identified were associated with co-infections 
with one or two of the other viruses.  The top three most common viral co-infections with 
WUPyV were HRV (29.1%), HBoV (20.8%), RSV (15.9%), HCoV-OC43 (13.9). And 58.5% of 82 
LRTI episodes in which HMPV were identified were associated with one of the other viruses. 
The most common viral co-infections with HMPV was HCoV-OC43 (n=8, 9.8%, p=0.035). 
 
Viral co-infections in children categorized as having bronchiolitis was 251 (58.2%) of 451 
episodes (Table 4.7). among the cases of bronchiolitis, HBoV was associated with another 
viral co-infection in 80.2% of 96 cases. Comparing detection of respiratory virus with another 
respiratory virus the significant viral co-infection was WUPyV were HRV (n=22; 32.3%; 
p=0.026), and HMPV (n=4; 5.9%; p=0.041), in addition HRV was significantly detected in 
27.1% HCoV-OC43 patients (p=0.004) 
 
The prevalence of at least two viral co-infections in children categorized as having clinical 
pneumonia was 280 (60.2%) of 464 cases (Table 4.8). Among the cases of clinical pneumonia, 
HBoV was associated with another viral co-infection in 84% of 94 cases. The most common 
viral co-infections being HRV (n=23, 24.5%), WUPyV (n=15, 19.7%) and RSV (n=8, 8.5%). 
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Table 4.6: Concurrent infection of newly emerging viruses and previously studied viruses in children that were hospitalized for 
lower respiratory tract infection 
 
Note: Viruses shown in italics were previously tested for by immunofluorescence assay or RT-PCR for hMPV.  
N: represent samples positive for respiratory virus with LRTI 
Virus HBoV 
N=190 
WUPyV 
N=144 
KIPyV 
N=63 
HCoV-
NL63 
N=29 
HCoV-
HKU1 
N=23 
HCoV-
OC43 
N=90 
HCoV-
229E 
N=4 
HRV 
N=29
7 
RSV 
N=2
09 
Influ 
A/B 
N=48 
PIV 1-
3 
N=36 
AdenoV 
N=22 
hMPV 
N=82 
Total (%) 
HBoV - 30 12 4 1 9 0 50 17 7 10 6 10 156 (82.1) 
WUPyV 30 - 10 6 4 20 1 42 23 7 2 3 12 160 (90) 
KIPyV 12 10 - 1 1 9 2 23 9 1 5 1 5 79 (79.7) 
HCoV-NL63 4 6 1 - 1 1 0 8 6 2 0 0 3 32 (91) 
HCoV-HKU1 1 4 1 1 - 5 1 4 4 0 0 0 4 25 (92) 
HCoV-OC43 9 20 9 1 5 - 1 27 11 5 3 1 8 100 (90) 
HCoV-229E 0 1 2 0 1 1 - 2 0 0 0 0 1 8 (50) 
HRV 50 42 23 8 4 27 2 - 46 7 11 1 21 242 (81.5) 
RSV 17 23 9 6 4 11 0 46 - 0 0 0 3 119 (41.0) 
Influ A/B 7 7 1 2 0 5 0 7 0 - 0 0 1 30 (62.5) 
PIV 1-3 10 2 5 0 0 3 0 11 0 0 - 0 0 31 (86.1) 
AdenoV 6 3 1 0 0 1 0 1 0 0 0 - 0 12 (54.5) 
Hmpv 10 12 5 3 4 8 1 21 3 1 0 0 - 68 (82.9) 
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Table 4.7:  Concurrent infection of newly emerging viruses and previously studied viruses in children that were hospitalized for 
bronchiolitis
Note: Viruses shown in italics were previously tested for by immunofluroesence assay or RT-PCR for hMPV.  
*N: represent samples positive for respiratory virus with bronchiolitis syndrome 
Virus HBoV 
*N= 96 
WUPyV 
N=68 
KIPyV 
N=23 
HCoV-
NL63 
N=10 
HCoV-
HKU1 
N=8 
HCoV-
OC43 
N=48 
HCoV
-229E 
N=2 
HRV 
N= 
154 
RSV 
N= 
117 
Influ 
A/B 
N=19 
PIV  
1-3 
N=18 
AdenoV 
N=9 
hMPV 
N=43 
Totals 
HBoV - 15 5 3 5 1 0 27 9 2 5 1 4 77 (80.2) 
WUPyV 15 - 3 1 11 3 1 22 12 3 1 2 4 78 (87.2) 
KIPyV 5 3 - 1 4 0 2 8 4 0 3 0 3 33 (69.7) 
HCoV-
NL63 
3 1 1 - 0 0 0 4 3 0 0 0 0 12 (83.3) 
HCoV- 
OC43 
5 11 4 0 - 2 1 13 5 2 0 1 5 49 (97.9) 
HCoV- 
HKU1 
1 3 0 0 2 - 2 1 2 0 0 0 1 12 (66.7) 
HCoV-
229E 
- 1 2 0 1 0 - 1 0 0 0 0 1 6 (33.3) 
HRV 27 22 8 4 13 13 1 - 20 4 3 0 14 117 (75.9) 
RSV 9 12 4 3 5 2 0 20 - 0 0 0 3 58 (49.6) 
Influ A/B 2 3 0 0 2 0 0 4 0 - 0 0 0 11 (57.9) 
PIV 1-3 5 1 3 0 0 0 0 3 0 0 - 0 0 12 (66.7) 
AdenoV 1 2 0 0 1 0 0 0 0 0 0 - 0 4 (44.4) 
hMPV 4 4 3 0 5 1 1 14 3 0 0 0 - 35 (81.4) 
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Table 4.8:  Concurrent infection of newly emerging viruses and previously studied viruses in children that were hospitalized for 
clinical pneumonia 
Note: Viruses shown in italics were previously tested for by immunofluroesence assay or RT-PCR for hMPV.  
N: represent samples positive for respiratory virus with clinical pneumonia diagnosis 
 
 
 HBoV 
N= 94 
WUPyV 
N=76 
KIPyV 
N=40 
HCoV-
NL63 
N=19 
HCoV-
HKU1 
N=15 
HCoV-
OC43 
N=42 
HCoV
-229E 
N=3 
HRV 
N= 
143 
RSV 
N= 
92 
Influ 
A/B 
N=29 
PIV 1-3 
N= 
18 
AdenoV 
N=13 
hMPV 
N=39 
Totals 
HBoV - 15 7 1 0 4 0 23 8 5 5 5 6 79 (84) 
WUPyV 15 - 7 5 1 9 0 20 11 4 1 1 8 82 (92.7) 
KIPyV 7 7 - 0 1 5 0 15 5 1 2 1 2 46 (86.9) 
HCoV-
NL63 
1 5 0 - 1 1 0 4 3 2 0 0 3 17 (89.5) 
HCoV-
HKU1 
0 1 1 1 - 3 1 3 2 0 0 0 3 14 (93.3) 
HCoV-
OC43 
4 9 5 1 3 - 0 14 6 3 3 0 3 51 (82.4) 
HCoV-229E 0 0 0 0 1 0 - 1 0 0 0 0 0 2 (66.7) 
HRV 23 20 15 4 3 14  - 26 3 8 1 7 124 ()86.7 
RSV 8 11 5 3 2 6 0 26 - 0 0 0 0 61 (66.3) 
Influ A/B 5 4 1 2 0 3 0 3 0 - 0 0 1 19 (65.5) 
PIV 1-3 5 1 2 0 0 3 0 8 0 0 - 0 0 19 (94.7) 
AdenoV 5 1 1 0 0 0 0 1 0 0 0 - 0 8 (61.5) 
hMPV 6 8 2 3 3 3 0 7 0 1 0 0 - 33 (84.6) 
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Figure 4.1:  Seasonal variation in identifying new respiratory viruses in children 
hospitalized for LRTI between January 2000 and December 2001 
 
4.5 Seasonality of respiratory viruses 
Seasonality was observed for the period of January 2000 to December 2001. Figure 4.1 
describes the seasonality of respiratory viruses in children with LRTI less than 2 years of age. 
The Y-axis shows the number of children with respiratory virus and the X-axis shows the 
months of the year for sampling. The peaks during winter months (April to August) were found 
for HRV, HBoV, WUPyV and KIPyV, HCoV-OC43 and HCoV-HKU1 virus over the period that the 
samples were collected. These months of the year represent Autumn-Winter seasons in South 
Africa. HCoV-229E was not included in the analysis as it did not have enough samples spread 
throughout. 
2000 2001 
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4.6 Demographics and clinical presentations associated with newly discovered 
respiratory viruses 
RSV, being the most common virus among the previously studied viruses was used as a 
referent group with which comparisons with other viruses were made in relation to 
demographic data, clinical data and laboratory information. A description of the demographic 
and clinical presentations of the LRTI episodes associated with RSV and the other viruses are 
shown in Tables 4.9-4.10.  
 
Children with LRTI who tested positive for RSV had a median age of 9.73 and in comparison 
with children who had LRTI episodes associated with HBoV, WUPyV, KIPyV and HRV were 
older; i.e. 10.8 months, 13.2 months, 12.2 months and 11.3 months, respectively (Table 4.9). 
There were, however, no differences in the percentages of babies who were born premature 
between the children who tested positive for RSV compared to whom tested positive for the 
other viruses. 
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Table 4.9:  Selected demographic features of children with specific respiratory viruses 
Demographic 
feature 
HBoV 
N=190 
WUPyV 
N=144 
KIPyV 
N=63 
HCoV-
NL63 
N=29 
HCoV-
OC43 
N=90 
HCoV-
HKU1 
N=23 
HRV 
N=297 
RSV 
209 
Age in moths 
[range] 
 
10.8 
[1.4-
23.3] 
p=0.03 
13.2 
[1.6-
23.9] 
p<0.01 
12.3 
[1.7-
23.8] 
p<0.01 
10.9 
[2.2-
23.3] 
p=0.14 
10.6 
[1.4-
24.0] 
p=0.26 
12.4 
[1.8-
22.0] 
p=0.19 
11.3 
[1.6-
23.8] 
p=0.02 
9.7 
[1.5-
23.8] 
 
Female, % 
43.7 
p=0.90 
41.0 
p=69 
47.6 
p=0.52 
55.2 
p=0.22 
42.2 
p=0.89 
52.2 
p=0.40 
37.4 
p=0.19 
43.1 
 
% of babies 
<37 wks GA 
at birth 
20.0 
p=0,92 
15.3 
p=0.29 
22.2 
p=0.65 
10.3 
p=0.31 
12.2 
p=0.12 
17.4 
p=0.53 
13.8 
p=0.08 
19.6 
 
GA: gestational age 
p-values compare to RSV 
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4.7 Clinical Signs and symptoms of identified respiratory viruses 
Table 4.10 described the clinical signs and outcome of children in whom the newly identified 
respiratory viruses were identified and in comparison to LRTI episodes in which RSV had been 
previously identified. Generally, the signs and outcome of LRTI episodes associated with the 
newly studied viruses were similar to that observed for RSV-associated LRTI. Exceptions to this 
(i.e. p<0.05) as shown in Table 4.10 included a higher prevalence of identifying bronchial 
breathing in LRTI episodes associated with KIPyV (60.3%; p=0.027) and HRV (4.04%; p=0.05) 
compared to RSV associated LRTI (0.95%),  Conversely, wheezing on chest auscultation was 
observed more frequently in RSV associated LRTI episodes (63.2%) compared to LRTI episodes 
associated with KIPyV (45.2%; p=0.011), HCoV-NL63 (41.4%; p=0.025) and HCoV-HKU1 (39.1%; 
p=0.025). There was no difference in oxygen saturation at admission, duration of hospital stay 
or case fatality rate among any of the newly studied viral LRTI episodes compared to RSV 
associated LRTI. There was a low overall case fatality rate including  four associated with HRV, 
three associated with HBoV and one each associated with WUPyV, KIPyV and HCoV-OC43. 
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Table 4.10:  Selected clinical signs and symptoms and outcome in children with LRTI 
Clinical feature 
HBoV 
N=190 
WUPyV 
N=144 
KIPyV 
N=63 
HCoV-
NL63 
N=29 
HCoV-
OC43 
N=90 
HCoV-
HKU1 
N=23 
HRV 
N=297 
RSV 
209 
Diarrhoea, n (%) 
49 
(25.8) 
p=0.32 
30 
(20.8) 
p=0.88 
12 
(19.1) 
p=0.67 
5 
(17.2) 
p=0.59 
14 
(15.6) 
p=0.23 
6 
26.1 
p=0.62 
63 
(21.4) 
p=0.96 
45 
(21.5) 
 
Seizures, n (%) 
5 
(2.7) 
p=0.86 
11 
(7.7) 
p=0.02 
2 
(3.2) 
p=0.66 
1 
(3.6) 
p=0.53 
4 
(4.5) 
p=0.46 
1 
(4.4) 
p=0.47 
15 
(5.1) 
p=0.13 
5 
(2.4) 
 
Vomiting, n (%) 
78 
(41.1) 
p=0.22 
54 
(37.5) 
p=0.07 
30 
(48.4) 
p=0.86 
10 
(34.5) 
p=0.20 
37 
(41.1) 
p=0.34 
11 
(47.8) 
p=0.95 
114 
(38.5) 
p=0.05] 
98 
(47.1) 
 
Bronchial 
breathing, n (%) 
6 
(3.2) 
p=0.16 
5 
(3.5) 
p=0.09 
4 
(6.4) 
p=0.03 
 
na 
 
2 
(2.22) 
p=0.59 
1 
(4.4) 
p=0.27 
12 
(4.0) 
p=0.05 
2 
(0.96) 
 
Oxygen 
supplementation, 
n (%) 
110 
(57.9) 
p=0.69 
93 
(64.6) 
p=0.36 
38 
(60.3) 
p=0.94 
17 
(58.6) 
p=0.90 
57 
(63.3) 
p=0.57 
13 
(56.5) 
p=0.76 
177 
(59.6) 
p=0.96 
125 
(59.81) 
 
Wheezing, n (%) 
110 
(57.9) 
p=0.28 
79 
(54.9) 
p=0.12 
28 
(45.2) 
p=0.01 
12 
(41.4) 
p=0.03 
56 
(62.2) 
p=0.88 
9 
(39.1) 
p=0.03 
177 
(59.6) 
p=0.42 
132 
(63.2) 
 
Oxygen 
saturation at 
admission (±SD) 
92.41 
(4.04) 
p=0.89 
91.76 
(5.05) 
p=0.22 
92.00 
(5.13) 
p=0.53 
91.28 
(3.46) 
p=0.12 
92.98 
(3.14) 
p=0.12 
92.96 
(2.77) 
p=0.38 
91.65 
(8.24) 
p=0.21 
92.35 
(3.38) 
 
Axillary temp 
(±SD) 
37.68 
(4.03) 
p=0.26 
37.28 
(0.87) 
p=0.66 
37.55 
(1.03) 
p=0.11 
37.14 
(0.85) 
p=0.46 
37.44 
(0.89) 
p=0.28 
37.77 
(0.93) 
p=0.01 
37.23 
(0.78) 
p=0.11 
37.25 
(0.74) 
 
Mean cough 
duration, days 
(±SD) 
4.30 
(3.87) 
p=0.11 
4.46 
(4.72) 
p=0.09 
4.32 
(4.66) 
p=0.25 
4.77 
(4.23) 
p=0.14 
4.28 
(4.07) 
p=0.21 
3.64 
(2.90) 
p=0.94 
4.09 
(4.30) 
p=0.28 
3.70 
(3.43) 
 
 
Mean weight, Kg 
 
8.04 
p=0.74 
9.06 
p=0.06 
9.26 
p=0.08 
8.41 
p=0.73 
8.42 
p=0.54 
8.64 
p=0.54 
8.60 
p=0.27 
8.15 
 
Mean hospital 
stay, days (±SD) 
2.54 
(3.35) 
p=0.22 
2.92 
(4.62) 
p=0.91 
2.33 
(2.77) 
p=0.20 
3.41 
(3.01) 
p=0.54 
2.48 
(3.70) 
p=0.29 
1.87 
(1.55) 
p=0.15 
2.59 
(3.78) 
p=0.26 
2.97 
(3.65) 
 
Case fatality rate, 
n (%) 
3 
(1.6) 
p=0.10 
1( 
0.69) 
p=0.41 
1 
(1.59) 
p=0.23 
 
0 
1 
(1.1) 
p=0.30 
 
0 
4 
(1.4) 
p=0.15 
 
0 
p-values compare to RSV 
na: not available 
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4.8 Clinical and laboratory findings of newly identified respiratory viruses 
Results of laboratory investigations undertaken in the children in whom the newly studied 
viruses were identified are shown in Table 4.11 and these episodes were compared to RSV 
associated LRTI episodes as a referent. A C reactive protein measurements of ≥40 mg/l, as a 
proxy measure of bacterial co-infection, was identified in a higher proportion of LRTI episodes 
associated with WUPyV (30.0%; p<0.0001), KIPyV (27.1%; p=0.017) and HCoV-NL63 (35%; 
p=0.03) than RSV associated LRTI episodes (17.0%). Similarly, indirect evidence of a greater 
proportion of bacterial coinfection as indicated by Procalcitonin of ≥0.2 ug/ml was evident for 
KIPyV (60%; p=0.023) and HCoV-OC43 (57.4%; p=0.0035) compared to RSV (40.3%). Other 
bacterial infections was found not significant when compared to RSV. 
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Table 4.11:  Clinical and laboratory findings in children with LRTI 
Clinical 
feature 
HBoV 
N=190 
WUPyV 
N=144 
KIPyV 
N=63 
HCoV-
NL63 
N=29 
HCoV-
OC43 
N=90 
HCoV-
HKU1 
N=23 
HRV 
N=297 
RSV 
209 
Median 
CRP-mg/dl 
[range] 
13 
[1-
446.2] 
18 
[1-
446.2] 
14.6 
[1-
331.2] 
18 
[1-
269.4] 
15 
[1-
315.2] 
24.95 
[0-251] 
 
13 
[1-344] 
 
10 
[1-290] 
 
CRP ≥40 
mg/dl; n 
(%) 
26 
(20.5) 
p=0.47 
30 
(30.0) 
p<0.01 
13 
(27.1) 
p=0.02 
7 
(35.) 
p=0.03 
13 
(22.4) 
p=0.37 
5 
(31.3) 
p=0.17 
44 
(21.9) 
p=0.27 
24 
(17.0) 
Median 
PCT-ug/ml 
[range] 
0.10 
[0.01-
44.2] 
p=0.79 
0.15 
[0.08-
69.7] 
p=0.01 
0.34 
[0.09-
30.9] 
p=0.02 
0.14 
[0.09-
5.1] 
p=0.52 
0.24 
[0.01-
13.9] 
p=0.09 
0.10 
[0.10-
11.3] 
p=0.33 
0.18 
[0.01-
105.6] 
p=0.02 
0.12 
[0.08-
47.5] 
PCT ≥0.2 
ug/ml; n 
(%) 
43 
(37.7) 
p=0.68 
43 
(47.8) 
p=0.28 
27 
(60.0) 
p=0.02 
8 
(44.4) 
p=0.74 
31 
(57.4) 
p=0.04 
6 
(42.9) 
p=0.85 
92 
(49.5) 
p=0.11 
50 
(40.3) 
CXR-AC; n 
(%) 
29 
(15.3) 
p=0.78 
28 
(19.4) 
p=0.44] 
15 
(23.8) 
p=0.17 
4 
(13.8) 
p=1.00 
19 
(21.1) 
p=0.31 
5 
(21.7) 
p=0.51 
55 
(18.5) 
p=0.51 
34 
(16.3) 
1Bacteria in 
BC; n (%) 
21 
(1.1) 
28 
(19.4) 
10 
(15.9) 
2 
(6.9) 
9 
(10.0) 
8 
(34.8) 
43 
(14.5) 
21 
(10) 
p-values compare to RSV 
na: not available 
CRP: C-reactive Protein 
PCT: Procalcitonin  
CXR-AC: Alveolar Consolidation on Chest Radiography 
1 Bacteria grown from patient’s blood culture 
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Table 4.12:  Bacteria found in blood cultures in children with LRTI and newly 
discovered respiratory viruses 
Clinical feature 
HBoV 
N=190 
WUPyV 
N=144 
KIPyV 
N=63 
HCoV-
NL63 
N=29 
HCoV-
OC43 
N=90 
HCoV-
HKU1 
N=23 
HRV 
N=297 
RSV 
209 
S.pneumoniae, n 
1 
p=0.73 
2 
p=0.37 
0 
p=0.77 
0 
p=0.87 
1 
p=0.52 
0 
p=0.90 
3 
p=0.45 
1 
H. influenzae, n 
0 
p=0.52 
0 
p=0.59 
0 
p=0.77 
0 
p=0.87 
0 
p=0.69 
0 
p=0.90 
2 
p=0.63 
1 
1 Other bacteria, 
n 
20 
p=0.40 
26 
p=0.01 
10 
p=0.11 
2 
p=0.47 
8 
p=0.91 
8 
p=0.001 
38 
p=0.19 
19 
No bacteria n  159 107 50 27 77 14 234 174 
p-values compare to RSV 
1 Other bacteria: Staphylococcus epidermidis, corynebacterium, Salmonella, nocardia species, 
Escherichia coli, Streptococcus agalactiae, Bacillus bacterium, Pseudomonas aeruginosa, 
Campylobacter, Staphylococcus aureus, Propionibacterium, Bimorrela catarrhalis, Viridans 
Streptococcus, Enterococcus faecalis, Alkaligines spp, Morganella morganii, Lactobacillus genus, 
Klebsiella genus, Acinetobacter lwoffii, Peptostreptococcus species, Candida albicans, Streptococcus 
milleri group, Micrococcus genus, Shigella flexneri, Neisseria meningitides, Haemophilus 
parainfluenzae, Citrobacter freundii, Mycobacterium tuberculosis, Neisseria subclavia, Escherichia 
vulneris. 
 
4.9 Bacterial co-infection  
Table 4.12 describes bacterial co-infections found in samples positive for respiratory viruses. Bacterial 
analysis on the blood in children with LRTI revealed that HCoV-HKU1 (n=8, 34.8%, p=0.000) and 
WUPyV (n=26, 18.1%, p=0.011) was found to be significantly different compared with RSV in diagnosis 
for other bacteria, there was no further significance observed. However possibility of contamination is 
observed for Corynebacteria. 
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LRTI episode: total number of LRTIs (bronchiolitis and pneumonia) 
 NPA done: nasopharyngeal aspirate performed 
Real time PCR done: number of samples available for testing of newly discovered respiratory 
viruses 
 
Figure 4.2: Summary of children who participated in the PCV trial under two years 
hospitalized for LRTI since 1 February 2000. 
 
HIV uninfected 
Vaccine recipients 
N=958 
 
N=1 
533 
Placebo recipients 
N=973 
 
N=933 N= 951 
 
N=455 (48.8%) N=440 (46.3) 
 
NPA done  
Real time PCR 
done 
LRTI 
episodes 
Study groups  
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Chapter 5: Discussion  
 
Respiratory viruses have been associated with pneumonia (Henrickson 1998; Madhi et al 2004; Arnold 
et al 2006; Fry et al 2007). Various studies have detected respiratory viruses in symptomatic and 
asymptomatic patients with respiratory illness (van Elden et al 2004; Allander et al 2005; Kesebir et al 
2006; Fry et al 2007; Han et al 2007; van de Pol et al 2009). Recently PCR has been used in laboratory 
and clinical settings as a diagnosis tool as it is an effective technique to detect genetic material of 
pathogens (van der Hoek et al 2004; Allander et al 2005; Woo et al 2005; Sloots et al 2006; Gaynor et 
al 2007). PCR is currently used to detect respiratory viruses as it has been recognized to be as sensitive 
and specific as other more conventional methods (virus isolation, cell culture and serology) (Heikkinen 
et al 2002; Lambert et al 2008). Hence PCR has increased the ability to detect viral pathogens including 
new and known respiratory viruses in clinical samples. In this study we have used PCR to identify and 
enumerate respiratory viruses, in HIV negative children less than 2 years old with lower respiratory 
tract infection. 
 
Prevalence of newly discovered respiratory viruses in children hospitalized for LRTIs 
In the current study the prevalence of newly described respiratory viruses was reported overall and it 
was stratified by PCV vaccination status; we also report on the prevalence thereof by clinical 
syndromes of bronchiolitis and clinical pneumonia. The prevalence’s reported are in general higher 
than previous published data on newly discovered respiratory viruses; nevertheless, the published 
data from various studies also report similar high prevalence of respiratory viruses associated when 
stratified by clinical syndromes LRTI (Choi et al 2006), pneumonia (Fry et al 2007; Franz et al 2010; 
Khadadah et al 2010), wheeze (Allander et al 2007; Smuts et al 2008) and bronchiolitis (Khadadah et al 
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2010). However bronchitis, bronchiolitis and pneumonia have been collectively associated with 
respiratory viruses (Gerna et al 2007). 
Prevalence, clinical presentation and co-infections with other viruses and bacteria for HBoV 
The overall prevalence of HBoV was high, 21.2% for LRTI, 22.3% for bronchiolitis and 20.3% for clinical 
pneumonia. In general, HBoV was more prevalent in South African children with LRTI in comparison to 
other studies, where the prevalence of HBoV ranged between 1% and 8% (Allander et al 2005; Smuts 
and Hardie 2006; Fry et al 2007). However, our data were similar to data describing the prevalence of 
HBoV associated with different clinical presentations, such as 19% in children with wheeze (Allander 
et al 2007) and 19.3% in children with acute respiratory illness (Bonzel et al., 2008). In the earlier 
studies (Allander et al 2005; Smuts H and Hardie D 2006), a conventional PCR method was used to 
enumerate HBoV, whereas the more recent studies (Allander et al 2007; Bonzel et al 2008) have used 
either quantitative or qualitative real time PCR. This difference in techniques can be a possible 
explanation for the higher prevalence of HBoV found in our study, as real time PCR is more specific 
and sensitive to detect genetic material in even the least concentrated samples. 
When stratified by PCV status, HBoV was most prevalent in the PCV-recipients compared to placebo-
recipients for all clinical syndromes. This is in contrast with data for most of the viruses described in 
this study whose prevalence was either unaffected, or even decreased with PCV vaccination. This 
unexpected result suggests that not only is HBoV unable to create the conditions which favour the 
outgrowth of vaccine serotypes of pneumococci, but also that LRTI associated with HBoV appears to 
be enhanced by PCV vaccination. This conclusion needs to be approached with caution due to bias in 
sample selection from the original sample set collected during the vaccine trial. The present data 
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suggests that continued surveillance for HBoV infections is needed in light of the rollout of PCV 
vaccination in South Africa. 
 
In 82% of LRTI episodes where HBoV was detected real-time PCR was also positive for at least one 
other respiratory virus. In other studies that have also reported on the prevalence of co-infections 
with HBoV in children with respiratory tract disease a 16% HBoV co-infection rate was observed 
(Bonzel et al 2008) and 43% (Manning et al 2006), 18% (Choi et al 2006), 39.1% (Weissbrich et al 2006) 
and 83% rates were detected in children with pneumonia (Fry et al 2007). This wide range is most 
likely due to differences in the number of pathogens reported as co-infections and the limitations in 
the methods used for detection. In the latter publications HBoV co-infections were more frequently 
associated with RSV (24%), HPIV (43%), HRV (42%) and Influenza (9%) (Fry et al 2007). Other studies 
showed co-infections of HBoV with RSV (14.3%) and adenovirus (7.1%) (Allander et al 2005) or with 
HRV (50%) and RSV (62%) (Fry et al 2007). In a South African study co-infection with a range of viral 
and bacterial pathogens was found in 37% of HBoV-positive children (Smuts and Hardie 2006). In our 
study we detected HBoV co-infections in: 26% with HRV, 8.9% with RSV, 3.2% with adenovirus and 
7.4% with HCoV-strains. The co-infections rates of HBoV with other viruses in our study are consistent 
with other studies that have reported on HBoV co-infections with other respiratory viruses in children 
younger than 24 months (Manning et al 2006; Smuts and Hardie 2006; Weissbrich et al 2006; Allander 
et al 2007; Fry et al 2007).  
 
Using data from a previous study in our unit, 1.1% of samples that were positive for HBoV were 
identified to have a correspondent positive bacterial blood culture, indicative of a bacteria-viral co-
infection. Of the HBoV positive samples 15.3% had a CXR-AC, 20.5% had an elevated CRP greater than 
40mg/dl and 37.7% had elevated PCT greater than 0.2 ug/ml. Three children who tested positive for 
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HBoV died. These findings are indicative that children infected with HBoV had severe (bacterial and 
viral) infections. Children who tested positive for HBoV experienced vomiting (41.1%), diarrhea 
(25.8%), seizures (2.7%), bronchial breathing (6.0%), wheezing (57.9%) and were in need of oxygen 
supplementation (57.9%) throughout treatment. Similarly, studies have found clinical symptoms 
including wheezing (Allander et al 2007) and oxygen supplementation (Fry et al 2007) in children with 
HBoV infection. Our findings show that HBoV prevalence is similar to RSV in LRTI clinical syndrome.  
One of the 3 children who died who were positive for HBoV was co-infected with HRV and the other 
two children had either bacterial infection from E. coli or from S. pneumoniae. C reactive protein 
values for the children with bacterial infections were 278 and 10 respectively. 
 
Prevalence, clinical presentation and co-infections with other viruses and bacteria for HRV 
The prevalence of HRV was 33.2% for LRTI, 33.8% for bronchiolitis and 30.8% for clinical pneumonia. 
Other studies have detected HRV in 32% (Talbot et al 2009; Franz et al 2010), 34% (Khadadah et al 
2010) and 56% (Choi et al 2006) of children with lower respiratory tract infection. The prevalence of 
HRV infection noted in studies in children with clinical pneumonia ranged from 22% (Franz et al 2010) 
to 42% (Khadadah et al 2010). In a study from Kuwait where 28% of the total specimens collected 
from LRTI episodes were positive for at least one of the 10 respiratory viruses tested showed that 37% 
and 42% of those presenting with bronchiolitis and pneumonia had HRV in their samples, respectively. 
(Khadadah et al 2010). In this stud 58% of the patients with LRTI were less than 1 year old (Khadadah 
et al 2010). These studies mentioned above used both conventional (Choi et al 2006; Khadadah et al 
2010) and real-time PCR (Talbot et al 2009; Franz et al 2010). Hence factors that play a role in 
estimating the prevalence of HRV in different populations, the age of the subjects sampled and 
method used to detect the respiratory viruses is essential in the analysis.  
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The HRV is notoriously known for its diversity, hence has a slight advantage over other viruses for 
spreading faster and higher pathogenetic potential (Arden et al 2010). Human rhinovirus ability to 
escape host immunity, attributed to the error prone viral RNA polymerase, enhances its ability to 
survive longer in patients by generating variants. Hot spots regions have been identified in the viral 
capsid genes VP1, VP2 and VP3 during acute infections (Cordey et al 2010). Therefore most previewed 
prevalence studies have utilized viral capsid genes to detect HRV. Our study also used these regions, 
as it increased the potential to detect more than one variant 
 
Despite a higher prevalence of HRV, co-infections of HRV with RSV (15.5%), HBoV (16.8%), WUPyV 
(14.1%), HMPV (7%), KIPyV (7.7%) and 3.7% with PIV 1-3 was found in our study. Other studies have 
shown co-infections of HRV with PIV 3 (7.1%) and RSV (50%) in children hospitalized for lower acute 
respiratory tract infections (Xiang et al 2008). Co-infections results from other studies have also shown 
that the most prevalent co-infections were due to RSV, HMPV, Influenza and PIV in children with 
asthma (Miller et al 2009). HRV-A and HRV-C strains of HRV show the higher degree of co-infections 
(Miller et al 2009).  
 
Patients’ clinical information from which respiratory viruses were detected is essential in linking the 
presence of a particular respiratory virus and to disease severity. Children positive for HRV were found 
to have the following symptoms: seizures (5.1%), diarrhoea (21.4%), vomiting (38.5%), bronchial 
breathing (4.0%) and 59.6% required oxygen supplementation and were also found to have wheezing. 
Other studies have shown a significant finding of fever and cough as clinical symptoms associated with 
HRV-A and HRV-C infection in children, respectively (Miller et al 2009). There were four case fatalities 
with HRV, of these deaths 3 patients had no bacterial or other viral infections and one patient was co-
infected with WUPyV. We have also shown that HRV prevalence is similar to that of RSV, suggesting 
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that HRV plays a role in the development and severity of LRTI in children less than 24 months. When 
stratified by PCV vaccination status, HRV had a similar prevalence to HBoV where it was more 
prevalent in the PCV vaccinated recipients for all clinical syndromes. 
 
Occurrence of HRV in the lower respiratory tract of children in our study and other studies supports 
the findings that HRV replicates and causes disease in the lower respiratory tract. In particular, a 
higher prevalence of clinical pneumonia indicates that infections with HRV of epithelial cells increases 
adherence of pneumococcus and that HRV impairs immune response of macrophages to bacterial 
lipopolysaccharide and lipoteichoic acid (Oliver et al 2008). 
 
Prevalence, clinical presentation and co-infections with other viruses and bacteria for 
HCoV-strains 
The human coronaviruses are viruses commonly known to cause mild respiratory symptoms including 
mild cough, running nose and malaise (van der Hoek et al 2007). However in immunocompetent 
individuals including children, HCoV are less prone to cause severe illness than in 
immunocompromised individuals due to their vulnerable immune system (van der Hoek et al 2007). In 
our study the overall prevalence of HCoV strains was 16.5% of LRTI, 15.9% for bronchiolitis and 17% 
for clinical pneumonia. Of the 4 strains tested the most prevalent strain was HCoV-OC43 in all clinical 
syndromes. Children who received placebo were more likely to have HCoV-OC43 infection than other 
strains of HCoV. Published data have shown that the majority (74.5%) of HCoV infections was 
associated with lower respiratory tract infections including bronchitis, bronchiolitis and pneumonia, 
compared to only 25.5% of upper respiratory tract infections which include rhinitis, pharyngitis and 
laryngitis (Gerna et al 2007). Other published reports have associated HCoV-NL63 and –OC43 with a 
substantial burden of lower respiratory illness and medically attended upper respiratory infections in 
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previously healthy children (Talbot et al 2009). Comparing human coronaviruses HCoV-OC43 and 
HCoV-NL63 had the highest infections in children diagnosed for LRTIs, bronchiolitis and clinical 
pneumonia in our study. Other studies have also found a higher prevalence of HCoV-OC43 and HCoV-
NL63 in children  (Hofmann et al 2005). In our study the least detected HCoV strain was the HCoV-
229E strain. From other studies evidence of low prevalence of HCoV-229E was found using both 
molecular (i.e. PCR) and serological methods (virus neutralization) in individuals suffering from URTIs 
and LRTIs and their findings are similar to our study (Hofmann et al 2005; Talbot et al 2009). Both 
HCoV-OC43 and HCoV-229E share similar genomic sequences and form the group I of HCoV, in 
addition these two strains cause severe respiratory diseases in children under the age of 2 years and 
immunocompromised adults (van der Hoek et al 2004; van der Hoek et al 2007). Our study also 
showed that HCoV-strains occur in children less than 2 years of age, with a median age ranging from 
9.73 months to 12.43 months. Nevertheless the difference in human coronaviruses prevalence is also 
noticeable in the populations around the world. 
 
Due to their differences in prevalence we should speculate whether these viruses exhibit similar 
clinical symptoms. Wheezing is often one of the clinical symptoms associated with the presence of 
respiratory viruses in children, followed by fever and coughing. In our study we report that compared 
to RSV both HCoV-NL63 and HCoV-HKU1 infections cause significant more wheezing 41.4%, p=0.03 
and 39.1%, p=0.03, respectively. Whereas other studies have indicated an association of URTIs and 
HCoV-NL63 (van der Hoek et al 2004), URTIs includes symptoms ranging from sneezing, sore throat, 
nasal discharge, cough, headache and myalgia (Baron S 1996). In addition a South African study also 
implicated the presence of HCoV-NL63 in children with acute wheezing (Smuts et al 2008). On the 
other hand, HCoV-NL63 has been associated with croup among infants with LRTIs (Choi et al 2006; 
Gerna et al 2007). Additional clinical data found in our study include elevated C reactive 
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measurements of more than ≥40 mg/dl that were observed in 35% of children with HCoV-NL63, 
indicative of an active inflammation. A highly bacterial infection was observed in 8% of children with 
HCoV-HKU1. In our study HCoV-NL63 positive children were found to have an elevated CRP 
measurement, indicative of a severe infection in these patients. 
 
Viruses with low prevalence may be misrepresented in terms of their associations with symptoms 
observed in the different studies, and this is true for HCoV-229E as it was the least detected virus 
amongst the coronaviruses in our study. In addition most studies are biased in the selection of 
samples, as specimens from sick patients are normally used in viral studies due to the need to 
diagnose and treat the patients. Hence future studies need to approach the question of asymptomatic 
viral prevalence in a manner that will educate researchers on the biological pathways respiratory 
viruses follow in both unhealthy and healthy individuals without or without symptoms. 
The highest rates of co-infections of HCoV-OC43 were with HMPV (8.9%), WUPyV (13.9%) and HRV 
(27.1%). Although the importance of these findings in terms of disease severity remains elusive in our 
case, however other studies have associated severe respiratory disease with multiple co-infections of 
HCoV-strains with other viruses as compared to single infection of HCoV strains in children less than 
one years of age (Gerna et al 2007).  
 
Prevalence, clinical presentation and co-infections with other viruses and bacteria for 
WUPyV 
The prevalence of WUPyV detected in our study was higher compared to most of the published 
available data, as mentioned above detection methodology and patient age have a heavy role in the 
detection of respiratory viruses. Human polyomaviruses have been shown to have high 
seroprevalence particularly in younger children and the elderly compared to young adults (Abedi 
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Kiasari et al 2008). In addition their abundance during childhood and the presence of other viruses 
may have some bearings to the development of severe disease (Han et al 2007). Thus, studies have 
come to a conclusion that human polyomaviruses establish persistent infection in the respiratory tract 
and become reactivated during respiratory disease of any cause (Han et al 2007; Abedi Kiasari et al 
2008). With that in notion, human polyomaviruses have been detected in asymptomatic patients (Han 
et al 2007; van de Pol et al 2009), in some cases these patient are immunosuppressed (Norja et al 
2007). Still the significance of these findings remains elusive, as it is further complicated by co-
infection with other respiratory viruses. 
 
We found an overall co-infection with WUPyV associated with LRTI in 90.0% of samples, 54.2% for 
bronchiolitis and 56.9% for clinical pneumonia. In overall LRTI high number of co-infections of WUPyV 
was observed with HRV (29.2%), HMPV (8.3%) and HCoV-OC43 (13.9%). In specimens collected from 
bronchiolitis cases the highest co-infection rates of WUPyV were with HRV (32.3%) and HBoV (22.1%). 
WUPyV co-infections in clinical pneumonia syndrome was not statistically significant but was the 
commonest co-infection with HBoV, as it had the highest co-infections than other viruses. Other 
studies have found co-infections of WUPyV with of HRV (40.5%) and HBoV (27.02%) (Gaynor et al 
2007) and with HMPV (50%) and with HBoV (25%) (Abedi Kiasari et al 2008) with various clinical 
presentations. Hence our data showed a higher prevalence of co-infection of WUPyV with HBoV. With 
this knowledge, WUPyV can be regarded as a virus that facilitates secondary infections by other 
viruses or bacteria or can be acquired early in life and reactivated later as a result of infection. 
 
In our study WUPyV infection was associated with seizures (7.7%). Although other studies have 
associated WUPyV infection with cough, fever and wheezing (Zhuang et al 2010), there was no 
association of WUPyV with clinical features from our findings when compared to RSV..  Clinical 
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features of the children in whom WUPyV was detected indicated a raised CRP to 20.5% ,a raised PCT 
level to 47.8% and 19.4% of CXR-AC. Hence, these clinical findings of WUPyV positives were associated 
with severe respiratory infection. In addition 19.4% of WUPyV positive specimens were associated 
with blood culture positive for various bacteria. One case fatality was observed in this scenario. In 
most studies published to date looking at WUPyV presence clinical data was not presented and only 
diagnosis of respiratory significance is indicated, hence this impedes to link the presence of the virus 
with the severity of disease. However, when we used clinical data WUPyV is implicated in playing a 
role in the severity of illness. 
 
Although we confirmed the presence of WUPyV in children with pneumonia, its role still remains 
unclear due to the high frequency of co-infection with other respiratory viruses. This lack of distinction 
is possibly associated with the use of highly sensitive PCR for detection of positive samples, which is 
able to detect pathogens even in low copy numbers, and is thus unable to discriminate between 
infection and asymptomatic carriage. 
 
Prevalence, clinical presentation and co-infections with other viruses and bacteria for KIPyV 
We found a prevalence of 8.6% of KIPyV in children with clinical pneumonia, 7.0% in children with LRTI 
and 5.3% in children with bronchiolitis. The prevalence of this virus in our samples was higher than 
most published data (normally less than 5%) for all syndromes (Bialasiewicz et al 2007; Abedi Kiasari et 
al 2008; van de Pol et al 2009; Venter et al 2009). Major difference in prevalence from our study 
compared to other study should be approached with caution, due to differences in methods used in 
processing the samples and analysis, also including the season of sampling that in our case included 
the winter months. Age of patient also plays an important role, as previous data supported the 
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presence of polyomaviruses early in childhood (Abedi Kiasari et al 2008). Bialasiewicz et al. also 
detected a higher prevalence in younger children (Bialasiewicz et al 2007). 
 
Comparing our findings we found that 14.3% of KIPyV positive specimens were co-infected with RSV, 
7.9% with HMPV and 1.6% with Influenza A/B and other studies have found 16.7% KIPyV co-infections 
with RSV, 4.2% with HMPV and 4.2% with Influenza A.  Similar results have been found in other 
studies (Allander et al 2007; Bialasiewicz et al 2007; Gaynor et al 2007; Abedi Kiasari et al 2008). 
Different publications have suggested that KIPyV infections do not cause disease, in particular 
pneumonia and bronchiolitis (Norja et al 2007; Jiang et al 2009). However, our findings show a 
significant association of KIPyV infection in the development of bronchiolitis and clinical pneumonia. 
Also children infected with KIPyV had a significantly increased CRP and PCT measurement than 
normal. 
 
Although there are some evidences that implicate that KIPyV has a role in respiratory infections, it still 
remains unclear that it causes disease due to a high frequency of co-detecting other respiratory 
viruses in KIPyV positives samples. In addition, lack of asymptomatic control in our studies and 
published studies complicates the link between respiratory tract disease and presence of KIPyV. 
 
Seasonality 
Although our data are spread throughout four seasons, peaks of respiratory viruses were observed 
during winter months (April to August) for HRV, HBoV, WUPyV and KIPyV, HCoV-NL63, HCoV-OC43 
and HCoV-HKU1. Similar results have been shown before for HBoV to occur in winter months in South 
Africa and Australia (Sloots et al 2006; Smuts and Hardie 2006). In addition KIPyV has been shown to 
have similar seasonality in Australia (Bialasiewicz et al 2007). Seasonality for WUPyV has been 
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demonstrated in the Northern hemisphere in the United Kingdom (Norja et al 2007). Human 
coronaviruses are also found in winter months particularly the strains HCoV-HKU1, HCoV-OC43 and 
HCoV-NL63 (Gaunt et al 2010). Temporal association for HCoV-229E season was not determined as we 
had only four positives for our study, similar sporadic trends have however been identified in the 
United Kingdom (Edinburgh) (Gaunt et al 2010). 
 
Limitation of the study 
The complete set of clinical samples collected during the surveillance period of the original parent 
study was not available for the present study due to the loss of samples. This loss was a result of 
either insufficient sample caused by repeat testing for other assays, or poor sample quality following 
prolonged storage. As a result, this study is limited by the potential bias in samples selection with 
respect to PCV vaccination status, and within the described clinical syndromes, and hence the true 
incidence of these viruses cannot be reported, and thus reporting is limited to the prevalence of the 
viruses within the context of these limitations. 
 
In addition we need to keep in mind that methodology and sampling procedure play a role in 
detecting true prevalence and incidences, making it difficult perform direct comparisons with other 
studies. Most studies have also showed that sampling during childhood can be biased in detecting 
higher rates of respiratory viruses in younger children than in older children. Our study was also 
biased as it only focused on the detection of respiratory viruses in infants. 
 
In the current study it was not possible to validate our real time PCR viral panel against a known 
method of detection. It would had been of interesting to use different methods such as conventional 
PCR vs. real time PCR to detect the viruses and to determine the difference between the two methods 
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in detection limit, sensitivity and sensitivity. A validated panel of known samples positive for each 
respiratory virus was not used in this study and this limited our knowledge on the performance of the 
PCR assay. However we optimized our PCR assay (concentration of reagents in the duplex reaction and 
determination of the detection limits by limiting serial dilutions of known positive samples) against the 
different viruses tested. 
 
Lastly our study had no asymptomatic patients to compare the prevalence of the respiratory viruses 
tested. This limited our knowledge in determining actual pathogens responsible for causing disease. 
Sero-epidemiological studies were also unfortunately impossible to perform in the cohort of our 
children. Additional data on HIV-infected children would have added more information with regards 
to the symptoms experience in both HIV-infected and un-infected, hence showing pathogenicity of the 
newly respiratory viruses in these children. 
 
Other limitations include the fact that molecular epidemiology was not included in the study, to show 
differences in strains in South Africa when compared with the rest of the world. Again knowledge of 
molecular sequences enhances ability to treat patients representing with lower respiratory tract infect 
and in the diagnostic tools to identify the viruses responsible. 
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Chapter 6: Conclusions 
 
 
The role of the newly discovered respiratory tract viruses is clinically significant, as these viruses exist 
in patients presenting with respiratory diseases in particular lower respiratory tract diseases. Although 
newly discovered respiratory viruses do not fulfill the totality of the Koch’s postulate stating that 
“microorganism must be isolated in diseased organism and grown in pure culture, microorganism 
should cause disease when introduced to healthy organism, and lastly the microorganism must be 
reisolated from the inoculate of diseased host and shown to be identical to the original causative 
agent”, nevertheless they fulfill part of Koch’s postulate “a microorganisms must be present in 
organisms suffering from diseases”. Therefore strategies such as vaccine interventions can be used to 
evaluate the role that these respiratory viruses play in elucidate etiology of pneumonia. Although 
respiratory viruses roles are indefinite additional studies of pneumonia in clinical settings have shown 
presence of respiratory viruses in patients with pneumonia (Madhi et al 2000; Madhi et al 2005; 
Arnold et al 2006; Allander et al 2007; Rudan et al 2008) 
 
The high detection rates of respiratory viruses is a true representation of respiratory tract infection, as 
molecular techniques such as PCR have been used in most studies to compare the prevalence of 
respiratory viruses in symptomatic and asymptomatic patients, indicating that PCR positives 
specimens are not residuals left over from previous infections from earlier infections of the virus of 
interest hence PCR is a indication of clinical and sub-clinical respiratory infection (Jartti  and Korppi 
2011). 
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The project presented in this thesis reveals the persistence of newly described respiratory viruses in 
children who suffered from pneumonia and their prevalence in children who receive placebo or PCV. 
Hence we showed that these viruses are also present in South Africa. Although their role is remains 
elusive, presence of newly respiratory viruses indicates that they assist in establishing lower 
respiratory infections including pneumonia and bronchiolitis. Further investigations of the study 
would include genotyping positive samples from this study and constructing phylogenetic lineage of 
respiratory viruses in South Africa. Additional studies focusing on HIV-infected children, older children 
particularly of school age and contacts of children with these respiratory viruses identified would aid 
in further understanding their role in respiratory disease.. 
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Appendix 
 
8.1.1 Lambda Phage Growth Protocol: Induction of Lambda lysogen 
 
 Grow culture of lambda lysogen overnight at 30°C. 
 Inoculate fresh LB and grow culture at 30°C till an OD of 0.2 is reached (540nm). 
 Transfer to 44°C waterbath –shake flask for 10min in waterbath. 
 Put culture on shaker at 37°C for 1hr 45min. 
 Microfuge culture for 1min. 
 Discard supernatant. 
 Vortex briefly to resuspend pellet in 0.5ml LM medium. (L broth and 10mM MgCl2). 
 Add 20 µL of chloroform. 
 Vortex for 10s 
 Store lysate (Figure 8.1) in cold 4°C. 
 
8.1.2 Titering lambda phage 
 
 Into a test tube add 2ml LB, 40ul 1M MgCl2, 20ul E.coli (stationary phase), vortex.  
 Add 2ml sloppy agar, mix by rolling between palms and pour onto LA plate with 10mM MgCl2.  
 When sloppy agar hardens, incubate at 42°C for 15 min. 
 In the meantime, prepare serial dilutions (10-1-10-6) of lambda in 20ul. 
 When the plate has dried spot 10ul of each dilution onto a single plate. Wait till spots are 
absorbed. Incubate at 37°C until plaques are visible. 
 Where single plaques are visible-count plaques in each spot:  
                                                         Pfu/ml= # of plaques X dilution factor/ vol spotted.  
8.1.3 Elution of Phage 
 Add 5ml if CSM to plate with plaques and store at 4°C for several hours (1-2hrs) with 
intermittent, gently shaking. 
 With a Pasteur pipette, harvest as much of the CSM as possible and place in a 15ml 
polypropylene tube. 
 Add 1ml of fresh CSM to the plate and store it for 15min in a tilted position to allow all of the 
fluid to drain into one area. Again remove the CSM and combine it with the harvest. Add 
0.1ml of chloroform to the pooled CSM, vortex briefly and centrifuge at 3000rpm for 10min at 
4°C. recover 8.1.4  
 
8.1.4 Cleaning phage from bacterial lysis 
 Add DNAse I and RNAse I at 1ug/ml each. Tilt the culture gently to mix in the enzymes without 
dispensing the chloroform. Incubate at room temperature for about 20min. 
 Split the lysate into two halves and centrifuge out the bacterial debris for 10min at 10000rpm. 
 Save 10ul of supernatant in eppendorf tube (use in column prep to check for DNA quality). 
Decant the remaining supernatant into new tubes. 
 Add 7ml of 20% Glycerol (w/v) PEG-8000 and 2.5M NaCl solution to each tube. Store ON on 
ice in 4°C. 
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 Centrifuge the PEG-precipitate for 15min at 8000 rpm. Decant the supernatant and invert the 
tubes over paper towel for 5-10min to drain. Don’t dry out pellet. 
 Resuspend each pellet in 1ml CSM. Rinse the sides of the tubes well since precipitate often is 
stuck to the sides rather than the bottom of the tube. 
 Pool the resuspensions for each phage in one of the tubes and transfer into new tube. Add 
2ml chloroform and centrifuge at 10000rpm for 10min. 
 Transfer the aqueous phase to two eppendorf tubes and perform two additional chloroform 
extractions 0.5ml of chloroform 
 Combine the aqueous phases and add an equal volume of 10mM Tris-HCL. 
 
 
 
 
 
Figure 8.1:  Lambda phage plaque lysate 
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Figure 8.2:  Applied Biosystems RT-PCR Protocol  
  
 
 
 
Figure 8.3:  Applied Biosystems RT-PCR cycling conditions on light cycler 
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Table 8.1:  Design of primer matrix reactions for all primers 
 
Components Quantity SI units 
Initial primer concentration 1600 nM 
Stock concentration 10000 nM 
Volume of primer in reaction 5 µl 
Total volume of reaction 25 µl 
# of wells for matrix 36   
Total volume 1st tube dilution  66 µl 
vol. of primer in 1st tube dilution 44 µl 
vol. of water to add in 1st tube 
dilution 
11 µl 
 
Table 8.2:  Q-PCR set-up for primer matrix reaction mix 
 
Components Initial 
concentration 
Final 
concentration 
Volumes 
(µL)/Reaction 
Volume (µL)/37 
Reactions 
Master mix 2X 1X 12.5 462.5 
Forward 
primer 
Various Various 5  
Reverse 
primer 
Various Various 5  
Probe 10µM 0.3µM 0.6 22.2 
DNA   1 37 
Water   0.9 33.3 
 
8.2 Primer optimizations 
Optimal primer concentrations were selected at the linear phase of reaction using linear 
phase graphs. Two criterions apply when selecting primer pairs and these are the Delta Rn and 
cycle threshold. Tables 8.3-8.4 illustrate the Delta Rn and the cycle thresholds. Control primer 
sets that were used to detect respiratory virus  are limiting primer pairs . In a PCR reaction 
detecting two targets at the same time it is necessary to limit primers in order for the majority 
of species to be stopped before it can limit common reactants available for amplification of 
the minority species. 
Hence varying the concentrations of primers, the observed trends are attributed to the 
change in occurring and detection of the target DNA. In this step we were observing how 
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different concentration of primers affects the detection of target DNA. Thus determining the 
pair which is most suitable for the detection of respiratory viruses. Table 8.5 illustrates primer 
matrix with Delta Rn and cycle threshold of 18 for bocavirus. For all respiratory viruses primer 
concentrations were chosen to ensure that in the PCR reaction they would detected the target 
virus yielded a maximum Delta Rn value and with a low cycle threshold. 
 
 
 
 
 
 
 
Graph 8.1:  Amplification curve of NDV showing log view of primer matrix 
Baseline 
Cycle 
threshold 
No Template 
Delta Rn 
ΔRn 
Rn
- 
Rn
+- 
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Table 8.3:  Cycle threshold and fluorescence intensity obtained from primer matrix  
 
   dilution of NDV and Lambda controls. 
 
Detector: 
NDV 
Reporter: 
FAM 
Threshold: 
0.086788 
Detector: 
LAMBDA 
Reporter: 
VIC 
Threshold: 
0.0329748 
Primers Cycle 
threshold 
Delta Rn Primers 
 
Cycle 
threshold 
Delta Rn 
 
1.3F/1.3R 20 3.5 1.3F/1.3R 13 1.2 
1.3F/0.6R 20 2.1 1.3F/0.6R 12 1.3 
1.3F/0.32R 20 1.1 1.3F/0.32R 13 0.8 
1.3F/0.16R 20 2.2 1.3F/0.16R 12 1.0 
1.3F/0.08R 20 1.6 1.3F/ 0.08R 13 0.8 
1.3F/0.04R 21 1.2 1.3F/0.04R 13 0.5 
0.6F/1.3R 21 3.5 0.6F/1.3R 12 1.3 
0.6F/0.6R 21 3.5 0.6F/0.6R 13 1.3 
0.6F/0.3R 21 3.4 0.6F/0.32R 13 1.3 
0.6F/0.16R 21 2.6 0.6F/0.16R 13 1.2 
0.6F/0.08R 21 1.7 0.6F/0.08R 13 0.8 
0.6F/0.04R 21 1.2 0.6F/0.04R 13 0.6 
0.32F/1.3R 21 3.4 0.32F/1.3R 13 1.3 
0.32F/0.6R 21 3.3 0.32F/0.6R 13 1.3 
0.32F/0.32R 21 3.2 0.32F/0.32R 13 1.3 
0.32F/0.16R 21 2.6 0.32F/0.16R 13 1.2 
0.32F/0.08R 21 1.8 0.32F/0.08R 13 1.0 
0.32F/0.04R 21 1.2 0.32F/0.04R 14 0.6 
0.16F/1.3R 21 2.6 0.16F/1.3R 14 1.1 
0.16F/0.6R 21 2.7 0.16F/0.6R 14 1.2 
0.16F/0.32R 21 2.7 0.16F/0.32R 14 1.3 
0.16F/0.16R 21 2.3 0.16F/0.16R 14 1.2 
0.16F/0.08R 21 1.8 0.16F/0.08R 14 0.9 
0.16F/0.04R 21 1.1 0.16F/0.04R 14 0.5 
0.08F/1.3R 21 1.8 0.08F/1.3R 14 1.0 
0.08F/0.6R 20 1.9 0.08F/0.6R 14 1.0 
0.08F/0.32R 21 1.7 0.08F/0.32R 14 1.0 
0.08F/0.16R 20 1.8 0.08F/0.16R 14 1.0 
0.08F/0.08R 22 1.3 0.08F/0.08R 14 0.8 
0.08F/0.04R 22 0.9 0.08F/0.04R 14 0.5 
0.04F/1.3R 22 1.3 0.04F/1.3R 14 0.8 
0.04F/0.6R 22 1.3 0.04F/0.6R 14 0.8 
0.04F/0.32R 22 1.4 0.04F/0.32R 14 0.8 
0.04F/0.16R 22 1.3 0.04F/0.16R 14 0.7 
0.04F/0.08R 22 1.1 0.04F/0.08R 14 0.6 
0.04F/0.04R 22 0.7 0.04F/0.04R 14 0.4 
      
R: Reverse primer and F: forward primer 
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Table 8.4:  Cycle threshold and fluorescence intensity obtained from primer matrix  
 
dilution of HCoV-OC43, HcoV-NL63 and HcoV-229E. 
 
Detector: 
HcoV-
OC43 
Reporter: 
FAM 
Threshold: 
0.231013 
 
Detector: 
HcoV-
NL63 
Reporter
: VIC 
 
Threshold: 
0.231013 
 
Detector: 
HcoV-229E 
 
Reporter: 
VIC 
 
Threshold: 
0.231013 
 
Primers Cycle 
threshold 
Delta Rn Primers 
 
Cycle 
threshold 
Delta Rn 
 
Primers 
 
Cycle 
threshold 
Delta Rn 
 
1.6F/ 1.6R 24 10.0 1.6F/ 1.6R 24 3.0 1.6F/ 1.6R 24 5.4 
1.6R / 0.8F 24 10.5 1.6R / 0.8F 24 2.3 1.6R / 0.8F 24 5.3 
1.6R /0.4F 24 10.7 1.6R /0.4F 24 2.2 1.6R /0.4F 24 5.0 
1.6R/0.2F 24 8.7 1.6R/0.2F 24 2.1 1.6R/0.2F 24 3.9 
1.6R/ 0.1F 24 11.5 1.6R/ 0.1F 25 3.1 1.6R/ 0.1F 24 5.6 
1.6R/0.05F 24 11.3 1.6R/0.05F 25 3.1 1.6R/0.05F 24 5.2 
0.8R/1.6F 24 10.6 0.8R/1.6F 25 3.1 0.8R/1.6F 24 4.9 
0.8F/0.8R 24 8.7 0.8F/0.8R 25 2.6 0.8F/0.8R 24 4.1 
0.8R/0.4F 24 12.3 0.8R/0.4F 25 2.9 0.8R/0.4F 24 5.1 
0.8R/0.2F 24 11.0 0.8R/0.2F 25 3.1 0.8R/0.2F 24 4.6 
0.8R/0.1F 24 10.2 0.8R/0.1F 25 3.1 0.8R/0.1F 24 4.4 
0.8R/0.05F 24 8.5 0.8R/0.05F 25 2.5 0.8R/0.05F 24 3.7 
0.4R/1.6F 24 10.8 0.4R/1.6F 26 2.8 0.4R/1.6F 24 4.5 
0.4R/0.8F 24 10.2 0.4R/0.8F 26 2.8 0.4R/0.8F 24 4.2 
0.4R/0.4F 24 9.0 0.4R/0.4F 26 2.8 0.4R/0.4F 24 3.8 
0.4R/0.2F 24 7.7 0.4R/0.2F 26 2.4 0.4R/0.2F 24 3.4 
0.4R/0.1F 25 10.0 0.4R/0.1F 26 3.0 0.4R/0.1F 24 5.4 
0.4R/0.05F 24 10.5 0.4R/0.05F 26 2.3 0.4R/0.05F 24 5.3 
0.2R/1.6F 24 10.7 0.2R/1.6F 26 2.2 0.2R/1.6F 24 5.0 
0.2R/0.8F 24 8.7 0.2R/0.8F 26 2.1 0.2R/0.8F 24 3.9 
0.2R/0.4F 24 11.5 0.2R/0.4F 26 3.1 0.2R/0.4F 24 5.6 
0.2R/0.2F 23 11.3 0.2R/0.2F 24 3.1 0.2R/0.2F 23 5.2 
0.2R/0.1F 25 10.6 0.2R/0.1F 26 3.1 0.2R/0.1F 24 4.9 
0.2R/0.05F 25 8.7 0.2R/0.05F 26 2.6 0.2R/0.05F 24 4.1 
R: Reverse primer and F: forward primer 
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Table 8.5:  Cycle threshold and fluorescence intensity obtained from primer matrix  
 
dilution of HcoV-HKU1, HRV and HboV 
 
Detector: 
HBoV 
Reporter: 
FAM 
Threshold: 
0.231013 
 
Detector: 
HRV 
 
Reporter: 
FAM 
 
Threshold: 
0.231013 
 
Detector: 
HCoV-HKU 
1 
Reporter: 
VIC 
 
Threshold: 
0.231013 
 
Primers Cycle 
threshold 
Delta Rn Primers 
 
Cycle 
threshold 
Delta Rn 
 
Primers 
 
Cycle 
threshold 
Delta Rn 
 
1.6F/ 1.6R 32 3.4 1.6F/ 1.6R 24 3.3 1.3F/ 1.3R 25 5.4 
1.6R / 0.8F 32 3.0 1.6R / 0.8F 24 3.5 1.3F/ 0.6R 25 5.3 
1.6R /0.4F 32 3.0 1.6R /0.4F 24 3.5 1.3F/0.32R 25 5.0 
1.6R/0.2F 33 3.1 1.6R/0.2F 24 3.3 1.3F/0.16R 25 3.9 
1.6R/ 0.1F 33 3.0 1.6R/ 0.1F 24 3.5 1.3F/ 0.08R 25 5.6 
1.6R/0.05F 33 2.9 1.6R/0.05F 24 3.4 1.3F/0.04R 25 5.2 
0.8R/1.6F 33 2.9 0.8R/1.6F 24 3.2 0.6F/1.3R 25 4.9 
0.8F/0.8R 33 2.8 0.8F/0.8R 24 2.8 0.6F/0.6R 25 4.1 
0.8R/0.4F 33 2.9 0.8R/0.4F 24 3.1 0.6F/0.32R 25 5.1 
0.8R/0.2F 33 2.5 0.8R/0.2F 24 3.2 0.6F/0.16R 25 4.6 
0.8R/0.1F 33 2.6 0.8R/0.1F 24 3.0 0.6F/0.08R 25 4.4 
0.8R/0.05F 33 2.4 0.8R/0.05F 24 2.6 0.6F/0.04R 25 3.7 
0.4R/1.6F 33 2.5 0.4R/1.6F 24 3.4 0.32F/1.3R 25 4.5 
0.4R/0.8F 33 2.1 0.4R/0.8F 24 3.1 0.32F/0.6R 25 4.2 
0.4R/0.4F 33 2.6 0.4R/0.4F 24 2.9 0.32F/0.32R 24 3.8 
0.4R/0.2F 33 1.8 0.4R/0.2F 25 2.3 0.32F/0.16R 25 3.4 
0.4R/0.1F 33 3.4 0.4R/0.1F 24 3.3 0.32F/0.08R 25 5.4 
0.4R/0.05F 33 3.0 0.4R/0.05F 24 3.5 0.32F/0.04R 25 5.3 
0.2R/1.6F 34 3.0 0.2R/1.6F 24 3.5 0.16F/1.3R 25 5.0 
0.2R/0.8F 34 3.1 0.2R/0.8F 24 3.3 0.16F/0.6R 25 3.9 
0.2R/0.4F 33 3.0 0.2R/0.4F 24 3.5 0.16F/0.32R 25 5.6 
0.2R/0.2F 33 2.9 0.2R/0.2F 24 3.4 0.16F/0.16R 25 5.2 
0.2R/0.1F 35 2.9 0.2R/0.1F 24 3.2 0.16F/0.08R 25 4.9 
0.2R/0.05F 35 2.8 0.2R/0.05F 24 2.8 0.16F/0.04R 25 4.1 
R: Reverse primer and F: forward primer 
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Table 8.6:  Cycle threshold and fluorescence intensity obtained from primer matrix  
 
dilution of WUPyV and KIPyV 
 
Detector: 
WUPyV 
Reporter: 
FAM 
Threshold: 
0.051122 
 
Detector: 
KIPyV 
 
Reporter: 
VIC 
 
Threshold: 
0.051122 
 
Primers Cycle 
threshold 
Delta Rn Primers 
 
Cycle 
threshold 
Delta Rn 
 
1.6F/ 1.6R 34 3.4 1.6F/ 1.6R 34 3.3 
1.6R / 0.8F 34 3.0 1.6R / 0.8F 34 3.5 
1.6R /0.4F 34 3.0 1.6R /0.4F 34 3.5 
1.6R/0.2F 34 3.1 1.6R/0.2F 34 3.3 
1.6R/ 0.1F 34 3.0 1.6R/ 0.1F 34 3.5 
1.6R/0.05F 34 2.9 1.6R/0.05F 34 3.4 
0.8R/1.6F 34 2.9 0.8R/1.6F 34 3.2 
0.8F/0.8R 34 2.8 0.8F/0.8R 35 2.8 
0.8R/0.4F 34 2.9 0.8R/0.4F 35 3.1 
0.8R/0.2F 34 2.5 0.8R/0.2F 34 3.2 
0.8R/0.1F 35 2.6 0.8R/0.1F 34 3.0 
0.8R/0.05F 35 2.4 0.8R/0.05F 35 2.6 
0.4R/1.6F 35 2.5 0.4R/1.6F 34 3.4 
0.4R/0.8F 34 2.1 0.4R/0.8F 34 3.1 
0.4R/0.4F 36 2.6 0.4R/0.4F 35 2.9 
0.4R/0.2F 36 1.8 0.4R/0.2F 35 2.3 
0.4R/0.1F 36 3.4 0.4R/0.1F 35 3.3 
0.4R/0.05F 36 3.0 0.4R/0.05F 35 3.5 
0.2R/1.6F 36 3.0 0.2R/1.6F 35 3.5 
0.2R/0.8F 36 3.1 0.2R/0.8F 34 3.3 
0.2R/0.4F 36 3.0 0.2R/0.4F 36 3.5 
0.2R/0.2F 36 2.9 0.2R/0.2F 36 3.4 
0.2R/0.1F 36 2.9 0.2R/0.1F 36 3.2 
0.2R/0.05F 36 2.8 0.2R/0.05F 36 2.8 
R: Reverse primer and F: forward primer 
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8.3 Limits of detection: Duplexing results 
Duplex PCR is the simultaneous detection of two target sequences. Real time PCR makes it 
possible to co-detect target sequences as it uses specific probes labeled with unique 
fluorescent dyes, hence using different wave lengths it is possible to detect different “colors”. 
Taqman probes are specifically used for this purpose. These probes consist of a quencher dye 
at the 3’ end of probe and a fluorescent dye at the 5’ end of probe. When the quencher dye is 
in close proximity to the fluorescent dye there is no emission of fluorescence, however during 
the annealing/extension period of the PCR reaction the 5’ nuclease activity of DNA 
polymerase enzyme cleaves the probe, separating the quencher dye from the fluorescent dye 
resulting in increase of fluorescence. The accumulation of the PCR product is detected and the 
fluorescence is monitored. The main goal of developing a duplex PCR is to accurately 
quantitate the amount of each target present without interference from competition or 
inhibition. In the present study HBoV was duplexed with Lambda DNA control. Table 8.7 
shows the 10 fold serial dilutions of both viruses. There was no competition and inhibition for 
both the Bocavirus and Lambda virus in the duplex PCR, as throughout the PCR Lambda 
maintains the cycle threshold at which corresponds to a single-plex PCR. Similar results were 
observed for all the duplex pairs of NDV and HCoV-2289E (Table 8.8), HRV and HCoV-HKU 1 
(Table 8.9), HCoV-NL63 and HCoV-OC43 (Table 8.10), WUPyV and KIPyV (Table 8.11), used in 
this thesis. 
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Table 8.7:  DNA matrix of Bocavirus and Lambda 
Bocavirus 
 
Lambda 
10E5 10E4 10E3 10E2 10E1 
10E5 18       \     18                18      \     20                18   \     26                18   \     29               ND    \     ND                
10E4 20        \     18                20       \     21                20   \     25                21   \     28                ND   \     ND                
10E3 22       \     18                22   \     21               22    \     25                22   \     28               ND    \     ND                
10E2 24       \     18                24      \    22                24    \   25               25      \     28                ND    \     ND                
10E1 ND      \     ND                ND      \     ND                ND      \     ND                ND      \     ND                ND      \     ND                
 
Table 8.8:  DNA matrix of NDV and HCoV-229E 
 
Table 8.9:  DNA matrix of HRV and HCoV- HKU 1 
 HRV 
 
 
HCoV-HKU 1 
10E5 10E4 10E3 10E2 10E1 
10E5 20       \     25                18   \     27               18    \     30                18   \     ND               ND   \     ND                
10E4 24       \     26                24   \     26                24   \     29                24   \     ND              ND    \     ND                
10E3 26       \     25               26    \     27              27     \     31                26   \     ND               ND   \     ND                
10E2 29       \     ND                30       \    ND                29       \     ND               29      \     ND                ND   \     ND                
10E1 ND      \     ND                ND      \     ND                ND      \     ND                ND      \     ND                ND      \     ND                
 
Table 8.10:  DNA matrix of HCoV-NL63 and HCoV- OC43 
HCoV-NL63 
 
 
HCoV-OC43 
10E5 10E4 10E3 10E2 10E1 
10E5 20     \     21              20       \     24                21   \     27                20   \     31               ND    \     ND                
10E4 23      \     20             23       \     24                23   \     26                23   \     32                ND   \     ND                
10E3 26      \     20              26       \     24               26    \     27                25   \     31               ND    \     ND                
10E2 30       \     20              31    \    25                31     \     27               30   \     31               ND     \     ND                
10E1 ND      \     ND                ND      \     ND                ND      \     ND                ND      \     ND                ND      \     ND                
 
NDVHCoV-
229E 
 
NDV 
10E5 10E4 10E3 10E2 10E1 
10E5 22       \     20                22   \     24                22   \     29                22   \     33               ND    \     ND                
10E4 25        \     19                25       \     23               20    \     27                21   \     31                ND   \     ND                
10E3 29       \     19               29    \     23               29    \     27                30   \     30               ND    \     ND                
10E2 36       \     19                32   \    23               33      \     27              32   \     31                ND     \     ND                
10E1 ND      \     ND                ND      \     ND                ND      \     ND                ND      \     ND                ND      \     ND                
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Table 8.11:  DNA matrix of WUPyV and KIPyV 
KIPyV 
 
 
WUPyV 
10E5 10E4 10E3 10E2 10E1 
10E5 30     \     30              20       \     33                21   \     37                20   \     39              ND     \     ND                
10E4 34      \     30             33       \     33                34   \     36                34   \     ND               ND   \     ND                
10E3 36      \     30              36       \     34               36    \     37                37     \    ND                 ND  \     ND                
10E2 39       \     39              ND     \    ND               ND      \     ND               ND      \     ND               ND      \     ND                
10E1 ND      \     ND                ND      \     ND                ND      \     ND                ND      \     ND                ND      \     ND                
 
Table 8.12:  Validation of PCR reactions 
Internal control Positive control Sample Result interpretation 
Positive Positive Positive Valid 
1Negative   Positive 
 
Positive Valid 
Positive Negative Positive Valid 
1IC negative due to competition for reagents with positive specimens 
 
